Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Neoplasms of the CNS

  Free Subscription


Articles published in J Neurooncol

Retrieve available abstracts of 828 articles:
HTML format



Single Articles


    November 2025
  1. CHANDLER KE, Grigorian JN, Pisharody VA, Chisango Z, et al
    Clinical and genomic factors differ in pediatric and adult pilocytic astrocytoma: a single-center experience with over 350 patients.
    J Neurooncol. 2025;175:539-547.
    PubMed     Abstract available


  2. KIM S, Son Y, Oh J, Kim S, et al
    Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022.
    J Neurooncol. 2025;175:673-685.
    PubMed     Abstract available


  3. BLOBNER J, Ruf V, Weller J, Teske N, et al
    Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.
    J Neurooncol. 2025;175:763-774.
    PubMed     Abstract available


  4. PAN Z, Ye X, Huang Y, Tai P, et al
    Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.
    J Neurooncol. 2025;175:857-868.
    PubMed     Abstract available


  5. CARDONA JJ, Park DJ, Al Gharyani MF, Wang JY, et al
    Stereotactic radiosurgery for intracranial and spinal adenoid cystic carcinoma: systematic review and illustrative case presentation.
    J Neurooncol. 2025;175:493-505.
    PubMed     Abstract available


  6. IUSUPOVSKAIA E, Isaev N, Antonian A, Boromangnaeva AK, et al
    Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.
    J Neurooncol. 2025;175:741-752.
    PubMed     Abstract available


  7. ZAYED S, Ruschin M, Atenafu EG, Chen H, et al
    Prognostic factors for local failure and overall survival in patients with epidural disease at the cauda equina following stereotactic body radiotherapy: a clinical, anatomic and dosimetric analysis.
    J Neurooncol. 2025;175:621-631.
    PubMed     Abstract available


  8. HUGHES JG, Cozzi FM, Phillips V, Price SJ, et al
    Shared decision-making interventions in neuro-oncology practice: a systematic review.
    J Neurooncol. 2025;175:471-479.
    PubMed     Abstract available


    October 2025
  9. DAS S, Walker-Dilks C, Nicholas G, Sahgal A, et al
    Executive summary of organizational guidance for the care of patients with central nervous system tumours in Ontario: consensus recommendations.
    J Neurooncol. 2025;175:419-429.
    PubMed     Abstract available


  10. CHEN W, Yuan J, Liu G, Cui L, et al
    Metagenomic next-generation sequencing and chromosomal copy number variation analysis in cerebrospinal fluid for the detection of meningeal carcinomatosis.
    J Neurooncol. 2025;175:175-181.
    PubMed     Abstract available


  11. WEI CZ, Deng H, Ashwat E, Albano L, et al
    Tumor control and motor function in patients with metastases located in the primary motor cortex after stereotactic radiosurgery.
    J Neurooncol. 2025;175:63-70.
    PubMed     Abstract available


  12. ABIKENARI M, Liu J, Ha JH, Annagiri S, et al
    Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.
    J Neurooncol. 2025;175:1-20.
    PubMed     Abstract available


  13. SARIKAYA C, Yaltirik CK, Varol E, Yuvruk E, et al
    The role of MRI patterns in predicting neurologic deficits in spinal ependymomas.
    J Neurooncol. 2025;175:313-322.
    PubMed     Abstract available


  14. ARENDT CT, Lohlau M, Roder L, Burger MC, et al
    Susceptibility- and T2*-weighted MRI features of CNS large B-cell lymphoma in a large single-center cohort: prevalence, patterns, and clinical associations.
    J Neurooncol. 2025;175:231-241.
    PubMed     Abstract available


  15. IVREN M, Yalman D, Ishak B, Ille S, et al
    Beyond surgical radicality in intramedullary spinal cord metastases: neurological function and systemic disease burden drive patient outcomes.
    J Neurooncol. 2025;175:431-442.
    PubMed     Abstract available


  16. GENSLER R, Xia Y, Horowitz MA, Abdulrahim M, et al
    Outcomes of leptomeningeal disease after only vertebral osseous metastases: a real-world analysis using the TriNetX database.
    J Neurooncol. 2025;175:219-229.
    PubMed     Abstract available


  17. ORSMOND A, De Sousa SMC, McCormack A
    The landscape of germline variants in breast and colorectal cancer susceptibility genes in patients with pituitary tumours.
    J Neurooncol. 2025;175:379-388.
    PubMed     Abstract available


  18. BECKHAM TH, Cha EE, Rooney MK, Tom MC, et al
    Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases.
    J Neurooncol. 2025;175:165-174.
    PubMed     Abstract available


  19. SHAH KH, Khalafallah AM, Knott MV, Berke CN, et al
    Predictors of prolonged length of stay in patients undergoing laser interstitial thermal therapy for intracranial tumors.
    J Neurooncol. 2025;175:91-99.
    PubMed     Abstract available


  20. RAMMELOO E, Young JS, Schouten JW, Bos EM, et al
    Preoperative assessment of tumor eloquence and resectability: an international survey.
    J Neurooncol. 2025;175:47-59.
    PubMed     Abstract available


    September 2025
  21. BASHIR S, Jian S, Hong W, Wang H, et al
    Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery.
    J Neurooncol. 2025 Sep 18. doi: 10.1007/s11060-025-05220.
    PubMed     Abstract available


  22. GURANDA A, Guresir E, Ruder AM, Giordano FA, et al
    Intra-cavitary radiotherapy for surgically resected brain metastases: a comprehensive analysis including an individual patient data meta-analysis of intraoperative radiotherapy (IORT) and brachytherapy (IBT).
    J Neurooncol. 2025 Sep 17. doi: 10.1007/s11060-025-05227.
    PubMed     Abstract available


  23. DEBOEUF L, Keraudy A, Picart T, Haddad G, et al
    Prevalence, natural history and surgical outcome of spinal meningiomas in NF2-related schwannomatosis.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05231.
    PubMed     Abstract available


  24. ROH H, Park C, Kim W, Choi J, et al
    Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05149.
    PubMed     Abstract available


  25. OI Y, Minamoto H, Taniyama I, Fukuzawa M, et al
    Novel predictors of tumor growth by exploratory quantitative analysis of radiomics features from MRI data for incidentally discovered meningioma.
    J Neurooncol. 2025 Sep 16. doi: 10.1007/s11060-025-05186.
    PubMed     Abstract available


  26. NAEWWAN N, Talabnin K, Trasaktaweesakul T, Khuansonthi P, et al
    Piperlongumine induces meningioma cell death via the ROS-mediated endoplasmic reticulum stress and the alteration of the ubiquitin-proteasome system.
    J Neurooncol. 2025 Sep 15. doi: 10.1007/s11060-025-05219.
    PubMed     Abstract available


  27. PAHWA B, Mahajan S, Pahwa N, Panico N, et al
    Linear regression models predict survival and complication rates in patients undergoing gamma knife radiosurgery for recurrent and residual craniopharyngiomas: a meta-analysis of 743 tumors.
    J Neurooncol. 2025 Sep 15. doi: 10.1007/s11060-025-05196.
    PubMed     Abstract available


  28. TREWIN-NYBRATEN CB, Lambert PC, Marienhagen K, Andreassen L, et al
    Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry.
    J Neurooncol. 2025 Sep 11. doi: 10.1007/s11060-025-05218.
    PubMed     Abstract available


  29. RENOVANZ M, Hippler M, Kuchen R, Doerner L, et al
    Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).
    J Neurooncol. 2025 Sep 10. doi: 10.1007/s11060-025-05223.
    PubMed     Abstract available


  30. SU M, Duan H, Lei Q, Tan Z, et al
    Utility and performance of cerebrospinal fluid cytology in discriminating central nervous system infections and brain tumors.
    J Neurooncol. 2025 Sep 10. doi: 10.1007/s11060-025-05214.
    PubMed     Abstract available


  31. AKUTAGAWA K, Miki S, Yamada E, Sakamoto N, et al
    Correction to: PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05203.
    PubMed    


  32. PRICE G, Frederico SC, Colan J, Rentzeperis F, et al
    Photodynamic therapy for glioblastoma: a narrative review.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05217.
    PubMed     Abstract available


  33. KOJUNDZIC I, Fritz JL, Said BI, Vuong S, et al
    Clinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05212.
    PubMed     Abstract available


  34. KAMBE A, Ochiai R, Makishima K, Yasuda S, et al
    Microvessel density as a prognostic and predictive biomarker in newly diagnosed glioblastoma: correlations with radiological features and bevacizumab efficacy.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05210.
    PubMed     Abstract available


  35. KESUMAYADI I, Kambe A, Amisaki H, Hosoya T, et al
    Prognostic value of hypertension timing for survival in glioblastoma patients receiving bevacizumab: a retrospective single centre analysis.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05209.
    PubMed     Abstract available


  36. EIBL T, Liebert A, Ritter L, Neher M, et al
    Role of patient frailty in resection of newly diagnosed motor eloquent glioblastomas guided by a navigated transcranial magnetic stimulation and tractography approach.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05206.
    PubMed     Abstract available


  37. DOIG M, Lee J, Kwok Y, MacEwan I, et al
    Impact of substructure radiation dose on health-related quality of life in children with brain tumors: a Pediatric Proton/Photon Consortium Registry (PPCR) study.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05211.
    PubMed     Abstract available


  38. SADAGOPAN NS, Gomez M, Tripathi S, Billingham LK, et al
    NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas.
    J Neurooncol. 2025 Sep 9. doi: 10.1007/s11060-025-05208.
    PubMed     Abstract available


  39. HALL JC, Goel K, Lozko Y, Chang SD, et al
    Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.
    J Neurooncol. 2025 Sep 7. doi: 10.1007/s11060-025-05201.
    PubMed     Abstract available


  40. HO A, Horbinski C, Sachdev S
    Thromboembolism in gliomas: an under-recognized danger.
    J Neurooncol. 2025 Sep 5. doi: 10.1007/s11060-025-05204.
    PubMed    


  41. ZARE A, Zare A, Hajikarimloo B, Mohammadi B, et al
    Radiosurgery for central nervous system ependymomas: a systematic review and meta-analysis.
    J Neurooncol. 2025;174:315-327.
    PubMed     Abstract available


  42. XIE Q, Hu J, Liu Y, Tabengwa GT, et al
    Retrospective study of leptomeningeal metastasis: unveiling the indolent and rapid progression phases.
    J Neurooncol. 2025;174:357-368.
    PubMed     Abstract available


  43. LIPATNIKOVA A, Kling T, Denes A, Carstam L, et al
    CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance?
    J Neurooncol. 2025;174:449-458.
    PubMed     Abstract available


  44. KRISCH JM, Ermoian RP, Indelicato DJ, Lee JY, et al
    Outcomes following radiation therapy for embryonal tumor with multilayered rosettes (ETMR): results from the Pediatric Proton/Photon Consortium Registry (PPCR).
    J Neurooncol. 2025;174:369-380.
    PubMed     Abstract available


  45. GIANTINI-LARSEN AM, Brown S, Reiner AS, Giandalone SD, et al
    Financial toxicity in pediatric and adolescent neurosurgical oncology.
    J Neurooncol. 2025;174:349-356.
    PubMed     Abstract available


  46. KHALAFALLAH AM, Susic N, Shah KH, Knott MV, et al
    Evaluating safety and feasibility of same-day discharge after laser interstitial thermal therapy: a pilot study with a matched control group.
    J Neurooncol. 2025;174:341-347.
    PubMed     Abstract available


  47. AREGA G, Hailu D, Fikad G, Nigusie M, et al
    Patterns, clinical presentations, and time to diagnosis in pediatric central nervous system tumors: insights from a pediatric neuro-oncology tumor board team at a tertiary referral hospital in Ethiopia.
    J Neurooncol. 2025;174:587-598.
    PubMed     Abstract available


  48. WANG J, Yang Q, Li X, Li Q, et al
    Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.
    J Neurooncol. 2025;174:667-687.
    PubMed     Abstract available


  49. CHEN JY, Schultz A, Khoury NM, Rangavajhula K, et al
    Optimizing workflows for metastatic central nervous system disease: a systematic review and proposed guidelines.
    J Neurooncol. 2025;174:557-585.
    PubMed     Abstract available


    August 2025
  50. ARACELI T, Haj A, Doenitz C, Stoerr EM, et al
    Complete resection of brain metastases - when does it matter?
    J Neurooncol. 2025 Aug 22. doi: 10.1007/s11060-025-05193.
    PubMed     Abstract available


  51. SHIH JJ, Jain B, Patel R, Jain U, et al
    Stereotactic radiosurgery for brain metastases: evolving practice patterns from the national cancer database (2004-2020).
    J Neurooncol. 2025 Aug 22. doi: 10.1007/s11060-025-05178.
    PubMed    


  52. GIORDANO C, Sassu CM, Marchetti C, Guerri G, et al
    Brain metastases from ovarian cancer: neuroradiological profile and survival overview of neurosurgical cases.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05192.
    PubMed     Abstract available


  53. WANG CY, Lin CF, Yang HC, Liu CY, et al
    Gamma knife radiosurgery for breast cancer brain metastasis: survival outcomes, prognotic factors, and the role of repeat treatment.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05188.
    PubMed     Abstract available


  54. LIN CA, Lin C, Rhodes CT, Moseley MC, et al
    Takeaways from meta-analysis: indications of combinational treatments for glioblastoma.
    J Neurooncol. 2025 Aug 21. doi: 10.1007/s11060-025-05205.
    PubMed     Abstract available


  55. YOGENDRAN LV, Kareddy A, Abbas SO, Scharf Z, et al
    Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.
    J Neurooncol. 2025 Aug 20. doi: 10.1007/s11060-025-05087.
    PubMed     Abstract available


  56. PENG TC, Hsieh MH, Lin CF, Kuan AS, et al
    Repeated stereotactic radiosurgery for high grade meningioma.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05165.
    PubMed     Abstract available


  57. NEU M, Shiban E, Krauss P, Sommer B, et al
    Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05152.
    PubMed     Abstract available


  58. SUN MZ, Contreras E, Treger J, Imbroane M, et al
    Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells.
    J Neurooncol. 2025 Aug 13. doi: 10.1007/s11060-025-05200.
    PubMed     Abstract available


  59. MAO M, Li Z, Zheng W, Xia H, et al
    Collagen type I alpha 1 induces radio-resistance in hypoxic glioblastoma cells by promoting autophagy.
    J Neurooncol. 2025 Aug 12. doi: 10.1007/s11060-025-05132.
    PubMed     Abstract available


  60. RAMIREZ FERRER E, Zuluaga-Garcia JP, Alzate JD, Mayorga-Corvacho J, et al
    Impact of healthcare disparities on the treatment and survival of patients with high-grade gliomas in Colombia: a multicenter inverse probability-weighted cohort analysis.
    J Neurooncol. 2025 Aug 12. doi: 10.1007/s11060-025-05198.
    PubMed     Abstract available


  61. BRASCHI EL, Trumble O, Casper A, Amdur RJ, et al
    Pattern of recurrence with 1.0 cm CTV in brain glioblastoma treated with radiotherapy.
    J Neurooncol. 2025 Aug 11. doi: 10.1007/s11060-025-05195.
    PubMed     Abstract available


  62. NISHIWAKI T, Kudo U, Nakamura S, Kuse Y, et al
    Synergistic antitumor and radiosensitizing effects of alpha-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma.
    J Neurooncol. 2025 Aug 11. doi: 10.1007/s11060-025-05194.
    PubMed     Abstract available


  63. URIAS E, DeCesaris C
    Comment on "A comparison of outcomes after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases: an international multi-center study".
    J Neurooncol. 2025 Aug 8. doi: 10.1007/s11060-025-05187.
    PubMed    


  64. KHATUA S, Bouffet E
    Summary of the collection on 'immunotherapy in pediatric brain tumors-an update'.
    J Neurooncol. 2025 Aug 6. doi: 10.1007/s11060-025-05191.
    PubMed    


  65. JENSEN LR, Maier AD, Juratli TA, Goutagny S, et al
    The concept, intention, and evaluation of the term treatment-refractory meningioma.
    J Neurooncol. 2025 Aug 4. doi: 10.1007/s11060-025-05154.
    PubMed     Abstract available


  66. CRISPI V, Peat S, Bolton WS, Chapman S, et al
    Mixed reality with 3D brain imaging for patient consultation in neurosurgery: an IDEAL stage 2a feasibility study.
    J Neurooncol. 2025;174:143-156.
    PubMed     Abstract available


  67. MO C, Liu X, Guo Y, Liang D, et al
    Clinical characteristics and pathological features of growth hormone-secreting pituitary adenoma combined with hyperprolactinemia.
    J Neurooncol. 2025;174:131-141.
    PubMed     Abstract available


  68. GARCIA CR, Highsmith K, Knight S, Andrade IP, et al
    Single center experience of IDH inhibitors in recurrent high-grade gliomas.
    J Neurooncol. 2025 Aug 1. doi: 10.1007/s11060-025-05183.
    PubMed     Abstract available


    July 2025
  69. HAGAN AJ, Hill RM, Kingston A, Bailey S, et al
    The utility of long-term methylphenidate in preserving intellectual development in survivors of childhood brain tumour.
    J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05177.
    PubMed     Abstract available


  70. BEVER N, Shukla IY, Ebada A, Wan B, et al
    Disparities in meningioma resection outcomes: a retrospective analysis of patients with public versus private insurance.
    J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05179.
    PubMed    


  71. LAN TL, Lin CF, Lee YY, Chang FC, et al
    Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates.
    J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05184.
    PubMed     Abstract available


  72. JAIN TK, Vohra M, Sharma BS, Loyal A, et al
    Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?
    J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05167.
    PubMed     Abstract available


  73. BANDOPADHAY J, Pichardo-Rojas PS, Cho R, Tavakkol E, et al
    Assessment of the RANO-resect criteria in elderly patients with glioblastoma.
    J Neurooncol. 2025 Jul 31. doi: 10.1007/s11060-025-05168.
    PubMed     Abstract available


  74. CHEN D, Ye L, Yu Z, Lei T, et al
    Whole exome sequencing study of adamantinomatous craniopharyngioma reveals the mutational characteristics of recurrent cases.
    J Neurooncol. 2025 Jul 29. doi: 10.1007/s11060-025-05061.
    PubMed     Abstract available


  75. LARIBI L, Scheepens JCC, Zamanipoor Najafabadi AH, Vos MJ, et al
    Correction to: Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.
    J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05147.
    PubMed    


  76. MATSUDA R, Takatani T, Hayashi H, Matsuoka R, et al
    Intraoperative neuromonitoring with direct cortical stimulation motor-evoked potentials in supratentorial glioma surgeries with preoperative moderate-to-severe motor weakness.
    J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05185.
    PubMed     Abstract available


  77. PICHARDO-ROJAS PS, Bandopadhay J, Nunez LC, Dono A, et al
    Impact of maximal and supramaximal resections on postoperative diffusion-weighted imaging changes and clinical outcomes in IDH-wildtype glioblastoma.
    J Neurooncol. 2025 Jul 28. doi: 10.1007/s11060-025-05169.
    PubMed     Abstract available


  78. PIENKOWSKI T, Mojsak P, Kowalczyk T, Cysewski D, et al
    Proteomic profiling reveals dynamic regulation of vesicle trafficking across glioma grades.
    J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05151.
    PubMed     Abstract available


  79. AYDEMIR I, Tutkun G, Akcit ET, Kocak O, et al
    Combined effects of escitalopram and vitamin E on phoenixin-20 secretion and neuroregulatory mechanisms in glioblastoma cells: a neuro-nutritional perspective.
    J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05176.
    PubMed     Abstract available


  80. LO SS, Halasz LM, Choi S, Kumthekar P, et al
    Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update.
    J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05074.
    PubMed     Abstract available


  81. LANMAN TA, Gross H, Faria CM, Miller JJ, et al
    Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors.
    J Neurooncol. 2025 Jul 23. doi: 10.1007/s11060-025-05155.
    PubMed     Abstract available


  82. DELGADO-LOPEZ PD, Montalvo-Afonso A, Garcia-Leal R, Martin-Garcia S, et al
    Surgical outcomes in octogenarian meningioma patients: a multicenter retrospective analysis of frailty and radiological predictors : Frailty in octogenarians undergoing meningioma resection.
    J Neurooncol. 2025 Jul 22. doi: 10.1007/s11060-025-05174.
    PubMed     Abstract available


  83. DU Z, Luo Y, Sun J, Long H, et al
    (18)F-NOTA-NFB PET/MRI in glioma recurrence: comparison with (11)C-methionine PET/MRI and contrast-enhanced MRI.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05159.
    PubMed     Abstract available


  84. KITE T, Bossinger B, Yadlapalli V, Jaffee S, et al
    Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05156.
    PubMed     Abstract available


  85. ALFONZO HOROWITZ M, Li M, Parker M, Arbuiso A, et al
    Incidence, demographics, and survival of patients with brain metastases from stage IV colorectal cancer: a population-based study from 2013 to 2023.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05107.
    PubMed     Abstract available


  86. ISHIKAWA T, Matsuda M, Kaneda Y, Ishikawa E, et al
    Hemagglutinating virus of Japan envelope encapsulating microRNA-34a-5p robustly induces apoptosis of malignant meningioma cells by suppressing survivin.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05172.
    PubMed     Abstract available


  87. HAEDENKAMP TM, Gotz L, Ansafi T, Gerken M, et al
    Dietary habits in relation to outcome and therapy-related toxicity in patients with glioblastoma - a retrospective cohort study.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05137.
    PubMed    


  88. PICHARDO-ROJAS PS, Hajikarimloo B, Sheehan JP
    Further points to consider regarding the resection strategy of eloquent brain metastasis in the era of postoperative stereotactic radiotherapy.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05153.
    PubMed     Abstract available


  89. VENKATARATNAM Y, Mukherjee V, Rai N, Mahalingaswamy M, et al
    Tunneling nanotubes between glioblastoma cells and T cells and hijack of mitochondria.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05150.
    PubMed     Abstract available


  90. PARKER M, Jiang K, Kalluri A, Arbuiso AG, et al
    Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05139.
    PubMed     Abstract available


  91. CAO H, Yan Z, Li M, Wang J, et al
    SIN1 facilitates glioma progression and is associated with the KRAS/ERK pathway.
    J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05166.
    PubMed     Abstract available


  92. LIU J, Meng Z, Wang R, Zhao G, et al
    CLOCK promotes proliferation of glioblastoma cells through acetylating PRPS1/2.
    J Neurooncol. 2025 Jul 19. doi: 10.1007/s11060-025-05163.
    PubMed     Abstract available


  93. SEOL MY, Choi SH, Yoon HI
    Targeting ataxia-telangiectasia mutated and cystine/glutamate antiporter enhances radiotherapy efficacy and tumor suppression in glioblastoma.
    J Neurooncol. 2025 Jul 17. doi: 10.1007/s11060-025-05128.
    PubMed     Abstract available


  94. CORAZZELLI G, Corvino S, Sigona L, Cioffi V, et al
    Evaluating the role of gross total resection in primary spinal cord glioblastoma: evidence from a multicenter cohort and meta-analysis.
    J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05158.
    PubMed     Abstract available


  95. LU MJS, Michaelsen SR, Locallo A, Eickhart-Dalboge CS, et al
    Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study.
    J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05162.
    PubMed     Abstract available


  96. CHEUNKARNDEE T, Ritter Z, Saint-Germain M, Ghanem P, et al
    Distinct size and spatial distribution patterns of ALK-inhibitor-naive versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases.
    J Neurooncol. 2025 Jul 16. doi: 10.1007/s11060-025-05148.
    PubMed     Abstract available


  97. POUR-RASHIDI A, Zandpazandi S, Hsu S, Shakeri A, et al
    Comparative analysis of monotherapy versus duotherapy with antiseizure medications for intraoperative and early postoperative seizure control in glioma patients undergoing awake craniotomy.
    J Neurooncol. 2025 Jul 15. doi: 10.1007/s11060-025-05133.
    PubMed     Abstract available


  98. HAISRAELY O, Vedala S, Al-Sharfeen A, Manzar GS, et al
    Glioblastoma in young adult patients: contemporary patterns of care and survival in the United States.
    J Neurooncol. 2025 Jul 15. doi: 10.1007/s11060-025-05135.
    PubMed    


  99. LAN R, Zhang N, Chen R, Chen J, et al
    Correction to: Identification of RASL11A as a gene conferring radiosensitivity in glioblastoma.
    J Neurooncol. 2025 Jul 8. doi: 10.1007/s11060-025-05142.
    PubMed    


  100. TORRES J, Bundrant BE, Dono A, Pichardo-Rojas PS, et al
    Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.
    J Neurooncol. 2025 Jul 3. doi: 10.1007/s11060-025-05143.
    PubMed     Abstract available


  101. MALLEREAU CH, Dannhoff G, Todeschi J, Severac F, et al
    Tips and tricks of spinal cord biopsy: insights from a multicenter series of 61 patients.
    J Neurooncol. 2025;173:719-729.
    PubMed     Abstract available


  102. LESHA E, Laird DG, Nichols CS, Miller LE, et al
    Variables associated with 90-day readmission following craniotomy for tumor in the pediatric population.
    J Neurooncol. 2025;173:759-767.
    PubMed     Abstract available


  103. DAGHER SA, Johnson JM, Mohamed RMM, Ansari S, et al
    Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy.
    J Neurooncol. 2025 Jul 1. doi: 10.1007/s11060-025-05146.
    PubMed     Abstract available


  104. ZHAO C, Liang B, Li X, Ma P, et al
    Anatomical distribution and prognostic heterogeneity in glioma: unique clinical features of occipital glioblastoma.
    J Neurooncol. 2025 Jul 1. doi: 10.1007/s11060-025-05144.
    PubMed     Abstract available


    June 2025
  105. KOCYIGIT S, Chavez MM, Orhun O, O'Brien J, et al
    Posterior parasagittal meningiomas display aggressive features independent of size: a multicenter analysis.
    J Neurooncol. 2025 Jun 26. doi: 10.1007/s11060-025-05103.
    PubMed     Abstract available


  106. DASGUPTA P, Lin H, Kumar G, Soomro Z, et al
    Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma.
    J Neurooncol. 2025 Jun 25. doi: 10.1007/s11060-025-05131.
    PubMed     Abstract available


  107. LIKHOMANOVA R, Oganesyan E, Yudintceva N, Fofanov G, et al
    Glioblastoma cell motility and invasion is regulated by membrane-associated heat shock protein Hsp70.
    J Neurooncol. 2025 Jun 24. doi: 10.1007/s11060-025-05127.
    PubMed    


  108. KRAUS LM, Goldberg M, Ursu E, Demirbag K, et al
    Postoperative hydrocephalus in patients with infratentorial brain metastases may be influenced by preoperative treatment: a single-center cohort study.
    J Neurooncol. 2025 Jun 23. doi: 10.1007/s11060-025-05125.
    PubMed     Abstract available


  109. NOCERA G, Sanvito F, Yao J, Oshima S, et al
    Independent histological validation of MR-derived radio-pathomic maps of tumor cell density using image-guided biopsies in human brain tumors.
    J Neurooncol. 2025 Jun 21. doi: 10.1007/s11060-025-05105.
    PubMed     Abstract available


  110. MADHUGIRI VS, Goulenko V, Seth L, Wang R, et al
    Evaluation of clinical and volumetric outcomes following adaptive gamma knife radiosurgery for brain metastases.
    J Neurooncol. 2025 Jun 20. doi: 10.1007/s11060-025-05138.
    PubMed     Abstract available


  111. ZULUAGA-GARCIA JP, Ramirez-Ferrer E, Peeters SF, DeMonte F, et al
    Management of skull base meningiomas with extracranial extension: resection, recurrence, and prognostic factors.
    J Neurooncol. 2025 Jun 19. doi: 10.1007/s11060-025-05111.
    PubMed     Abstract available


  112. JUNG K, Sivadas SD, Fitzgerald X, Phillips C, et al
    Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases.
    J Neurooncol. 2025 Jun 19. doi: 10.1007/s11060-025-05121.
    PubMed     Abstract available


  113. ROSE ML, Bajaj BVM, Jimenez R, Dennehy S, et al
    Quality of life in pediatric patients treated with adjuvant proton radiation for craniopharyngiomas.
    J Neurooncol. 2025 Jun 18. doi: 10.1007/s11060-025-05112.
    PubMed     Abstract available


  114. WANG Q, Wang H, Hong W, Bashir S, et al
    Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis.
    J Neurooncol. 2025 Jun 18. doi: 10.1007/s11060-025-05045.
    PubMed     Abstract available


  115. LOESCHNER D, Wagle PR, Jung A, Neumeister A, et al
    The communication of a high-grade glioma diagnosis- patients' reflections and perspectives based on a study-specific questionnaire.
    J Neurooncol. 2025 Jun 17. doi: 10.1007/s11060-025-05129.
    PubMed     Abstract available


  116. SHEN H, Li J, Jia Y, Liu F, et al
    The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.
    J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05090.
    PubMed     Abstract available


  117. FAN H, Li X, Zhao Y, Song L, et al
    Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.
    J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05116.
    PubMed     Abstract available


  118. SEIDEL JA, Alder L, Salama AKS, Anders CK, et al
    Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.
    J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05120.
    PubMed     Abstract available


  119. CHAKRAVARTI S, Tang L, Shah HA, Singh A, et al
    Patient nutritional status is associated with surgical site infections in meningioma patients undergoing craniotomy for tumor resection.
    J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05123.
    PubMed     Abstract available


  120. MAO Y, Tang L, Horowitz MA, Myneni S, et al
    Automated feature learning and survival prognostication in grade 4 glioma using supervised machine learning models.
    J Neurooncol. 2025 Jun 16. doi: 10.1007/s11060-025-05099.
    PubMed     Abstract available


  121. YARLAGADDA S, Zhang Y, Saxena A, Kutuk T, et al
    Assessment of outcomes and machine Learning-based models to predict local failure risk following stereotactic radiosurgery for small brain metastases.
    J Neurooncol. 2025 Jun 13. doi: 10.1007/s11060-025-05092.
    PubMed     Abstract available


  122. TURAN T, Emmez OH, Kaymaz AM, Gonenc A, et al
    Clinical utility of GAL-8, ITGBeta-1, and HIF-1alpha as non-invasive diagnostic and prognostic biomarkers for assessing glioma.
    J Neurooncol. 2025 Jun 13. doi: 10.1007/s11060-025-05110.
    PubMed     Abstract available


  123. GIDRON Y, Katan N, Mansour N, Grossman R, et al
    The prognostic and protective roles of heart-rate variability in glioblastoma: making GBM less vague.
    J Neurooncol. 2025 Jun 12. doi: 10.1007/s11060-025-05010.
    PubMed     Abstract available


  124. AKUTAGAWA K, Miki S, Yamada E, Sakamoto N, et al
    PIK3R2 immunostaining status predicts prognosis in patients with newly diagnosed glioblastoma treated with an autologous tumor vaccine.
    J Neurooncol. 2025 Jun 12. doi: 10.1007/s11060-025-05102.
    PubMed     Abstract available


  125. KREATSOULAS DC, Kim J, Damante M, Orr A, et al
    A novel lesion severity index to predict 90-day postoperative survival in brain metastasis patients.
    J Neurooncol. 2025 Jun 11. doi: 10.1007/s11060-025-05109.
    PubMed     Abstract available


  126. METWALLY SM, El-Ayadi M, Maher E, El-Minawi MS, et al
    Impact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma.
    J Neurooncol. 2025 Jun 10. doi: 10.1007/s11060-025-05098.
    PubMed     Abstract available


  127. SAVIOLA F, Zigiotto L, Jovicich J, Sarubbo S, et al
    Predicting attention deficits and functional recovery after glioma resection through functional executive networks: insights from dynamic properties.
    J Neurooncol. 2025 Jun 10. doi: 10.1007/s11060-025-05079.
    PubMed     Abstract available


  128. LARIBI L, Scheepens JCC, Zamanipoor Najafabadi AH, Vos MJ, et al
    Antiseizure medication in patients with meningioma: a retrospective cohort study on the long-term impact on depression, anxiety and neurocognitive functioning.
    J Neurooncol. 2025 Jun 6. doi: 10.1007/s11060-025-05025.
    PubMed     Abstract available


  129. JACQUERIE A, Macamo A, Hoeben A, Eekers DBP, et al
    IDO2-AhR axis as central regulator of the kynurenine pathway in glioblastoma.
    J Neurooncol. 2025 Jun 5. doi: 10.1007/s11060-025-05106.
    PubMed     Abstract available


  130. ROBERT SM, Toth A, Lev S, Bowden SG, et al
    Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.
    J Neurooncol. 2025 Jun 5. doi: 10.1007/s11060-025-05083.
    PubMed     Abstract available


  131. WHITTLE IR
    Complete resolution of peritumoral FLAIR hyperintensity is infrequent in surgically treated patients with intracranial meningiomas.
    J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05097.
    PubMed    


  132. WEI CZ, Shanahan R, Puccio D, Deng H, et al
    A comparison of outcomes after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases: an international multi-center study.
    J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05093.
    PubMed     Abstract available


  133. MARINO S, Menna G, Doglietto F, Quaranta D, et al
    A white matter-centered approach to investigate recurrence pathways in high-grade gliomas: a single-center retrospective study.
    J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05050.
    PubMed     Abstract available


  134. RAYMOND C, Yao J, Kolkovsky ALL, Feiweier T, et al
    Super-resolution sodium MRI of human gliomas at 3T using physics-based generative artificial intelligence.
    J Neurooncol. 2025 Jun 3. doi: 10.1007/s11060-025-05094.
    PubMed     Abstract available


  135. TINKA P, Pokorna P, Kyr M, Pavelka Z, et al
    Individualized therapeutic approaches for relapsed and refractory pediatric ependymomas: a single institution experience.
    J Neurooncol. 2025;173:479-488.
    PubMed     Abstract available


  136. JIN J, Qin J, Qi X, Zhang J, et al
    Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis.
    J Neurooncol. 2025;173:419-428.
    PubMed     Abstract available


  137. NOBEL H, Ofer J, Borenstein SF, Limon D, et al
    Long-term impact of bevacizumab for the treatment of brain radiation necrosis.
    J Neurooncol. 2025;173:289-296.
    PubMed     Abstract available


  138. WOO PYM, Pu JKS, Li LF, Wong DKK, et al
    Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.
    J Neurooncol. 2025;173:317-330.
    PubMed     Abstract available


    May 2025
  139. NAKHATE V, Ly I, Muzikansky A, Rapalino O, et al
    Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
    J Neurooncol. 2025 May 28. doi: 10.1007/s11060-025-05020.
    PubMed     Abstract available


  140. YADAV N, Xiao A, Zhong Q, Kumar P, et al
    Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-beta signaling.
    J Neurooncol. 2025 May 28. doi: 10.1007/s11060-025-05089.
    PubMed     Abstract available


  141. IBANEZ-JULIA MJ, Bataller L, Cabello-Murgui FJ, Nguyen-Them L, et al
    Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors.
    J Neurooncol. 2025 May 27. doi: 10.1007/s11060-025-05091.
    PubMed     Abstract available


  142. BERTOLINI G, Trombini T, Zenesini C, Mazza S, et al
    Prognostic impact of second surgical resection in IDH wildtype recurrent glioblastoma following chemo-radiation therapy: a propensity score analysis cohort study.
    J Neurooncol. 2025 May 27. doi: 10.1007/s11060-025-05096.
    PubMed     Abstract available


  143. SCHRODER C, Haghighi N, Phillips C, Udovicich C, et al
    A feasibility trial of delayed resection for brain metastases following pre-operative stereotactic radiosurgery.
    J Neurooncol. 2025 May 26. doi: 10.1007/s11060-025-05081.
    PubMed     Abstract available


  144. SENTURK YE, Canturk EM, Peker A, Yuzkan S, et al
    Predictive value of early DCE and DSC perfusion MRI parameters for midterm clinical outcomes in lung cancer brain metastases treated with stereotactic radiosurgery.
    J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05054.
    PubMed     Abstract available


  145. HANI L, Nasiri D, Gachter A, Klimov A, et al
    Reconsideration of the resection strategy of eloquent brain metastasis in the era of postoperative stereotactic radiotherapy: a comparative analysis with non-eloquent metastasis.
    J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05075.
    PubMed     Abstract available


  146. VAN DIJCK JTJM, Ardon H, Balvers RK, Bos EM, et al
    Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry.
    J Neurooncol. 2025 May 23. doi: 10.1007/s11060-025-05080.
    PubMed     Abstract available


  147. LI Y, Wang Y, Han X, Xu J, et al
    Correction to: Glioma-derived SPARCL1 promotes the formation of peritumoral neuron-glioma synapses.
    J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05069.
    PubMed    


  148. TANG T, Wu Y, Dong X, Zhai X, et al
    Multimodal MRI radiomics enhances epilepsy prediction in pediatric low-grade glioma patients.
    J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05073.
    PubMed     Abstract available


  149. ZHOU M, Wu W, Wang Y, Zhang B, et al
    Targeting COL5A1 enhances anoikis thus attenuating malignancy of glioblastoma via inhibiting the Wnt/beta-catenin signaling pathway.
    J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05036.
    PubMed     Abstract available


  150. WILLIAMS A, Neth B, Webb M, Schwartz J, et al
    Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis.
    J Neurooncol. 2025 May 22. doi: 10.1007/s11060-025-05028.
    PubMed     Abstract available


  151. SHU Y, Dong Y, Li B, Wang Y, et al
    Knockdown of STK39 inhibits lung cancer brain metastasis by suppressing the CPSF4/NFkappaB/COX2 pathway.
    J Neurooncol. 2025 May 21. doi: 10.1007/s11060-025-05072.
    PubMed     Abstract available


  152. ABIKENARI M, Regev A, Himic V, Choi J, et al
    The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.
    J Neurooncol. 2025 May 20. doi: 10.1007/s11060-025-05082.
    PubMed     Abstract available


  153. ALDEEVA IA, Glebova EV, Sarkisyan RA, Romanova EN, et al
    Long-term neurocognitive sequelae in pediatric medulloblastoma survivors treated according to the HIT protocol.
    J Neurooncol. 2025 May 16. doi: 10.1007/s11060-025-05070.
    PubMed     Abstract available


  154. BOMMIREDDY A, Mayo ZS, Reddy CA, Billena C, et al
    Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases.
    J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05062.
    PubMed     Abstract available


  155. IYER HG, Ariwodo OK, Mckevitt C, Meade PS, et al
    Predictors of return to work following surgery in patients with glioblastoma: a retrospective multicenter study.
    J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05066.
    PubMed     Abstract available


  156. WEIDL D, Capper D, Onken J, Liu I, et al
    Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
    J Neurooncol. 2025 May 13. doi: 10.1007/s11060-025-05068.
    PubMed     Abstract available


  157. SHUKLA IY, Ebada A, Bever N, Traylor JI, et al
    Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.
    J Neurooncol. 2025 May 12. doi: 10.1007/s11060-025-05057.
    PubMed     Abstract available


  158. BADVE C, Nirappel A, Lo S, Orringer DA, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines for the role of imaging in newly diagnosed WHO grade II diffuse glioma in adults: update.
    J Neurooncol. 2025 May 8. doi: 10.1007/s11060-025-05043.
    PubMed     Abstract available


  159. NA MK, Oh Y, Lee D, Park J, et al
    Comparison of the biological characteristics of glioblastoma tumorspheres obtained from fresh and cryopreserved glioblastoma tissues.
    J Neurooncol. 2025 May 5. doi: 10.1007/s11060-025-05052.
    PubMed     Abstract available


  160. PICHARDO-ROJAS PS, Garcia-Torrico F, Espinosa-Cantu CB, Rodriguez-Elvir FA, et al
    Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007-2023).
    J Neurooncol. 2025 May 2. doi: 10.1007/s11060-025-05058.
    PubMed     Abstract available


  161. ZHENG GH, Zhang YW, Liu YX, Liu WH, et al
    Clinical characteristics and prognostic factors of primary spinal subependymoma: a single-center cohort study and systematic review.
    J Neurooncol. 2025;172:675-685.
    PubMed     Abstract available


  162. ANDEREGGEN L, Christ E
    Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.
    J Neurooncol. 2025;172:613-623.
    PubMed     Abstract available


  163. GU W, Zhang W, Wu Z, Cai Y, et al
    Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance.
    J Neurooncol. 2025;172:587-597.
    PubMed     Abstract available


  164. FILHO AM, Znaor A, Sunguc C, Zahwe M, et al
    Cancers of the brain and central nervous system: global patterns and trends in incidence.
    J Neurooncol. 2025;172:567-578.
    PubMed     Abstract available


  165. MANSOORIAN S, Schmidt M, Weissmann T, Delev D, et al
    Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.
    J Neurooncol. 2025 May 1. doi: 10.1007/s11060-025-05042.
    PubMed     Abstract available


  166. FINK L, von Sass C, Golla H, Voltz R, et al
    Epidemiology and palliative care of in-patient cerebral metastases cases in Germany.
    J Neurooncol. 2025;173:37-48.
    PubMed     Abstract available


  167. THERKELSEN KE, Cao T, Roy-O'Reilly M, Stocksdale B, et al
    Molecular testing and targeting for solid tumors with CNS metastases.
    J Neurooncol. 2025;173:1-10.
    PubMed     Abstract available


  168. MENNA G, Riva D, Marino S, Garber J, et al
    Simulation tools in neuro-oncological surgery: a scoping review of perioperative and training applications.
    J Neurooncol. 2025;173:21-35.
    PubMed     Abstract available


  169. FRAZZINI V, Mathon B, Shor N, Nichelli L, et al
    The Mickey Mouse's hand sign in brain MRI points out multinodular and vacuolating neuronal tumors in mesial temporal lobe structures.
    J Neurooncol. 2025;173:217-223.
    PubMed     Abstract available


  170. LIU KX, Salans M, Easwaran TP, Phuong C, et al
    The association between postoperative photon radiotherapy dose and disease control and salvage treatment in pediatric and adolescent ependymoma: a multi-institutional investigation.
    J Neurooncol. 2025;173:167-177.
    PubMed     Abstract available


  171. RYU H, Li X, Lee TH, Kim TM, et al
    Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: implications for hippocampal avoidance irradiation.
    J Neurooncol. 2025;173:95-104.
    PubMed     Abstract available


    April 2025
  172. WAGNER-BALLON C, Moreira A, Houessinon A, Boone M, et al
    Defining end-of-life in glioblastoma multiforme: a systematic review.
    J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05051.
    PubMed     Abstract available


  173. LA ROSA A, Mittauer KE, Rzepczynski AE, Chuong MD, et al
    Temporospatial tumor dynamic changes in glioblastoma during radiotherapy.
    J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05060.
    PubMed     Abstract available


  174. MICHEL A, Rauschenbach L, Karadachi H, Gumus M, et al
    Surgical treatment of multiple breast cancer brain metastases: clinical characteristics and factors impacting postoperative survival.
    J Neurooncol. 2025 Apr 29. doi: 10.1007/s11060-025-05048.
    PubMed     Abstract available


  175. DIN SU, Sufiyan S, Shah AA, Fatima H, et al
    HMGA1 as a prognostic biomarker for gliomas: expression patterns, survival correlations, and clinical insights from a Pakistani cohort.
    J Neurooncol. 2025 Apr 28. doi: 10.1007/s11060-025-05031.
    PubMed     Abstract available


  176. MARWAHA AS, Shepard MJ, Karlovits SM, Herbst J, et al
    Advancements in adaptive MR-guided radiotherapy for high-grade gliomas.
    J Neurooncol. 2025 Apr 24. doi: 10.1007/s11060-025-05053.
    PubMed     Abstract available


  177. YI GZ, Lin JF, Lu YX, Li ZY, et al
    Clinical, pathological, radiological features and prognosis of epithelioid glioblastoma: a retrospective single center study.
    J Neurooncol. 2025 Apr 23. doi: 10.1007/s11060-025-05046.
    PubMed     Abstract available


  178. AKDEMIR EY, Gurdikyan S, Reyes TC, Odia Y, et al
    Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients.
    J Neurooncol. 2025 Apr 22. doi: 10.1007/s11060-025-05038.
    PubMed     Abstract available


  179. LALLY AR, Ghosh SR, Pecorari IL, Reynolds J, et al
    Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis.
    J Neurooncol. 2025 Apr 22. doi: 10.1007/s11060-025-05049.
    PubMed     Abstract available


  180. PERRON R, Iorio-Morin C, Chytka T, Simonova G, et al
    International multicenter study of stereotactic radiosurgery for bladder cancer brain metastases.
    J Neurooncol. 2025 Apr 18. doi: 10.1007/s11060-025-05039.
    PubMed     Abstract available


  181. YUN YC, Jende JME, Garhofer F, Wolf S, et al
    Combined peritumoral radiomics and clinical features predict 12-month progression free survival in glioblastoma.
    J Neurooncol. 2025 Apr 17. doi: 10.1007/s11060-025-05037.
    PubMed     Abstract available


  182. DUFFAU H
    The capability to successfully study and to be graduated in students who underwent awake surgical resection for a low-grade glioma.
    J Neurooncol. 2025 Apr 17. doi: 10.1007/s11060-025-05044.
    PubMed     Abstract available


  183. LAPIDUS AH, Devitt B, Herbison H, Tran S, et al
    A Delphi study of current practices and establishing consensus regarding assessment of fitness to drive among patients with brain tumours.
    J Neurooncol. 2025 Apr 16. doi: 10.1007/s11060-025-05030.
    PubMed     Abstract available


  184. LIU X, Hao S, Sun S, Xie J, et al
    Increased cortical iron deposition in glioma patients: a quantitative susceptibility mapping study.
    J Neurooncol. 2025 Apr 16. doi: 10.1007/s11060-025-05027.
    PubMed     Abstract available


  185. RASHID NS, Lamba N, Catalano PJ, Elhalawani H, et al
    Impact of brain metastasis size at the time of radiotherapy on local control and radiation necrosis.
    J Neurooncol. 2025 Apr 15. doi: 10.1007/s11060-025-05023.
    PubMed     Abstract available


  186. DIAZ LS, Agrup M, Askild A, Embring A, et al
    Acute side effects of proton and photon radiotherapy for medulloblastoma: a retrospective national multicenter study.
    J Neurooncol. 2025 Apr 15. doi: 10.1007/s11060-025-05016.
    PubMed     Abstract available


  187. ZSCHERNACK V, Pinto G, Friker LL, Klein R, et al
    Pitfalls in the evaluation of CDKN2A copy number status in meningioma.
    J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05029.
    PubMed     Abstract available


  188. LI Y, Wang Y, Han X, Xu J, et al
    Glioma-derived SPARCL1 promotes the formation of peritumoral neuron-glioma synapses.
    J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05007.
    PubMed     Abstract available


  189. SANVITO F, Kryukov I, Yao J, Teraishi A, et al
    Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.
    J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05019.
    PubMed     Abstract available


  190. BAXTER SM, Bjorge T, Bjerkvig R, Cardwell C, et al
    Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales.
    J Neurooncol. 2025 Apr 10. doi: 10.1007/s11060-025-04996.
    PubMed     Abstract available


  191. SUFIYAN S, Salam H, Ilyas S, Amin W, et al
    Prognostic implications of DNA methylation machinery (DNMTs and TETs) expression in gliomas: correlations with tumor grading and patient survival.
    J Neurooncol. 2025 Apr 10. doi: 10.1007/s11060-025-05032.
    PubMed     Abstract available


  192. NOGUCHI M, Koide Y, Shindo Y, Aoyama T, et al
    Repeat stereotactic radiosurgery for recurrent brain metastases: a retrospective comparison of local progression and distant brain metastases after prior radiosurgery.
    J Neurooncol. 2025 Apr 9. doi: 10.1007/s11060-025-05035.
    PubMed     Abstract available


  193. PANDEY K, Mishra S, Garg K, Garg A, et al
    Patterns of response following gamma knife radiosurgery for tectal plate gliomas.
    J Neurooncol. 2025 Apr 9. doi: 10.1007/s11060-025-05034.
    PubMed     Abstract available


  194. SUN Y, Estevez-Ordonez D, Atchley TJ, Nabors B, et al
    The association of neighborhood-level deprivation with glioblastoma outcomes: a single center cohort study.
    J Neurooncol. 2025 Apr 7. doi: 10.1007/s11060-025-05002.
    PubMed     Abstract available


  195. FU AY, Bernstein K, Zhang J, Silverman J, et al
    Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases.
    J Neurooncol. 2025 Apr 4. doi: 10.1007/s11060-025-05026.
    PubMed     Abstract available


  196. ZHUANG L, Yin X, Liu X, Liu D, et al
    Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single?center retrospective study.
    J Neurooncol. 2025;172:461-470.
    PubMed     Abstract available


  197. ZHAO X, Zhang Y, Wang Y, Ren X, et al
    Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.
    J Neurooncol. 2025;172:481-490.
    PubMed     Abstract available


  198. BAKES E, Cheng R, Manucat-Tan N, Ramaswamy V, et al
    Advances in molecular prognostication and treatments in ependymoma.
    J Neurooncol. 2025;172:317-326.
    PubMed     Abstract available


  199. LAN R, Zhang N, Chen R, Chen J, et al
    Identification of RASL11A as a gene conferring radiosensitivity in glioblastoma.
    J Neurooncol. 2025 Apr 1. doi: 10.1007/s11060-025-05013.
    PubMed     Abstract available


    March 2025
  200. RIEGEL DC, Bureau BL, Conlon P, Chavez G, et al
    Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting.
    J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-04946.
    PubMed     Abstract available


  201. TAORI S, Wei Z, Hadjipanayis CG, Niranjan A, et al
    Long-term outcomes following upfront single-session gamma knife stereotactic radiosurgery for large volume meningiomas.
    J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05000.
    PubMed     Abstract available


  202. TOSI U, Schwartz TH
    Resection of craniopharyngiomas: comparison between gross total resection and subtotal resection with adjuvant radiation.
    J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05017.
    PubMed     Abstract available


  203. GUO H, Li X, Tong H, Fang J, et al
    Longitudinal analysis of radiologic progression patterns in glioblastoma: investigating prognosis using a multi-state model.
    J Neurooncol. 2025 Mar 31. doi: 10.1007/s11060-025-05022.
    PubMed     Abstract available


  204. HOROWITZ MA, Brown NJ, Gendreau J, Pennington Z, et al
    The association of hospital volume status with treatment and survival outcomes of intracranial meningioma patients: a multivariable analysis of the National Cancer Database.
    J Neurooncol. 2025 Mar 28. doi: 10.1007/s11060-025-05011.
    PubMed     Abstract available


  205. SHEN H, Zhou Z, Zhang X, Xu M, et al
    Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients.
    J Neurooncol. 2025 Mar 26. doi: 10.1007/s11060-025-05015.
    PubMed     Abstract available


  206. GHOSH SR, Lally AR, Pecorari IL, Reynolds J, et al
    The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysis.
    J Neurooncol. 2025 Mar 25. doi: 10.1007/s11060-025-05012.
    PubMed     Abstract available


  207. MAZA EJL, Pavoni JF, Leoni RF
    Early and late structural brain changes after radiation therapy: an MRI study in glioma patients.
    J Neurooncol. 2025 Mar 21. doi: 10.1007/s11060-025-05008.
    PubMed     Abstract available


  208. NEIMANTAITE A, Carstam L, Gomez Vecchio T, Haggstrom I, et al
    Survival prediction with radiomics for patients with IDH mutated lower-grade glioma.
    J Neurooncol. 2025 Mar 18. doi: 10.1007/s11060-025-05006.
    PubMed     Abstract available


  209. MULLER HL
    Long-term quality of life and hypothalamic dysfunction after craniopharyngioma.
    J Neurooncol. 2025 Mar 17. doi: 10.1007/s11060-025-04987.
    PubMed     Abstract available


  210. DE DOMENICO P, Gagliardi F, Roncelli F, Snider S, et al
    Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.
    J Neurooncol. 2025 Mar 13. doi: 10.1007/s11060-025-04989.
    PubMed     Abstract available


  211. MA ST, Ahn YC, Lim DH, Lee JI, et al
    Gamma Knife Radiosurgery for optic nerve sheath meningioma: comparison of efficacy and costs with radiotherapy under Korean health insurance system.
    J Neurooncol. 2025 Mar 11. doi: 10.1007/s11060-025-04986.
    PubMed     Abstract available


  212. CERRETTI G, Bosio A, Librizzi G, Pintacuda G, et al
    Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.
    J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-04992.
    PubMed     Abstract available


  213. HARARY PM, Rajaram S, Hori YS, Park DJ, et al
    The spectrum of radiation therapy options for craniopharyngioma: a systematic review.
    J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-05001.
    PubMed     Abstract available


  214. SARIKONDA A, Quraishi D, Mitchell Self D, Sami A, et al
    Introducing the operative value index for glioma surgery: an integration of quality-adjusted life years with time-driven activity-based costing.
    J Neurooncol. 2025 Mar 10. doi: 10.1007/s11060-025-04997.
    PubMed     Abstract available


  215. NETH BJ, Kraft RM, Eschbacher KL, Johnson DR, et al
    Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.
    J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04994.
    PubMed     Abstract available


  216. LAAJAVA J, Niemela M, Korja M
    Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma- a retrospective study of 279 meningioma patients.
    J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04964.
    PubMed     Abstract available


  217. TORRES-TENOR JL, Garcia-Leal A, Hui D, Bruera E, et al
    Unscheduled hospitalization as a potential trigger for specialist palliative care referral in patients with high grade glioma: a retrospective analysis in a tertiary hospital.
    J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04993.
    PubMed     Abstract available


  218. FARAJ CA, McCutcheon IE, Gubbiotti MA, Perni S, et al
    Extra-central nervous system metastasis from high-grade glioma: a single-institution experience.
    J Neurooncol. 2025 Mar 6. doi: 10.1007/s11060-025-04977.
    PubMed     Abstract available


  219. FARES J, Wan Y, Gurung B, Nazar T, et al
    Spatial invasion patterns of temporal lobe glioblastoma after complete resection of contrast-enhancing tumor.
    J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04991.
    PubMed     Abstract available


  220. JOSHI N, Mueller S, Kline C
    Current clinical trials for craniopharyngiomas: what's on the horizon?
    J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-024-04899.
    PubMed     Abstract available


  221. SHIREMAN JM, Distler E, Schepp C, Tao Y, et al
    Impact of pregnancy on the treatment and outcomes of glioma: a cohort study.
    J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04961.
    PubMed     Abstract available


  222. AGNER KE, Larkins MC
    Population-based histologic analysis of craniopharyngioma demographics and treatment in the US from 2000 to 2020.
    J Neurooncol. 2025 Mar 5. doi: 10.1007/s11060-025-04988.
    PubMed     Abstract available


  223. SAINI S, Gadet JAMA, Freeman GJ, Chiocca EA, et al
    Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.
    J Neurooncol. 2025 Mar 4. doi: 10.1007/s11060-025-04978.
    PubMed     Abstract available


  224. ADIDA S, Sefcik RK, Gerszten PC
    Comment on "The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management".
    J Neurooncol. 2025 Mar 3. doi: 10.1007/s11060-025-04983.
    PubMed    


  225. VERMA O, Mishra S, Tripathi M, Sheehan JP, et al
    Role of stereotactic radiosurgery for intracranial epidermoid tumors: a systematic review to assess its safety, efficacy, and complication profile.
    J Neurooncol. 2025;172:13-30.
    PubMed     Abstract available


  226. ZHU JW, Shum M, Qazi MA, Sahgal A, et al
    Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.
    J Neurooncol. 2025;172:31-40.
    PubMed     Abstract available


  227. DINAKARAN D, Moore-Palhares D, Yang F, Hill JB, et al
    Precision radiotherapy with molecular-profiling of CNS tumours.
    J Neurooncol. 2025;172:51-75.
    PubMed     Abstract available


  228. JALAL AHB, Gunn H, Gunasekara B, Gan HW, et al
    Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience.
    J Neurooncol. 2025;172:257-263.
    PubMed     Abstract available


  229. OSAKO R, Hayano A, Kawaguchi A, Yamanaka R, et al
    Single-cell RNA-seq reveals diverse molecular signatures associated with Methotrexate resistance in primary central nervous system lymphoma cells.
    J Neurooncol. 2025;172:163-173.
    PubMed     Abstract available


  230. ONISHI S, Yamasaki F, Amatya VJ, Yonezawa U, et al
    Prognostic value of immunohistochemical staining for H3K27me3 and EZH2 in astrocytoma, IDH-mutant.
    J Neurooncol. 2025;172:185-194.
    PubMed     Abstract available


  231. HASKELL-MENDOZA AP, Gonzalez AT, Reason EH, Flusche AM, et al
    The LITT Fit in neuro-oncology: indications, imaging, and adjunctive therapies.
    J Neurooncol. 2025;172:1-11.
    PubMed     Abstract available


    February 2025
  232. YU J, Ren L, Wu T, Hua L, et al
    Establishment and transcriptomic characteristics of radio-resistant meningioma cell lines.
    J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-025-04966.
    PubMed     Abstract available


  233. WU Q, Chen S, Xie X, Yan H, et al
    Glioblastoma- derived exosomes (GBM-Exo) regulate microglial M2 polarization via the RAC1/AKT/NRF2 pathway.
    J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-024-04934.
    PubMed     Abstract available


  234. LI Y, Shi J, Liu C, Ma D, et al
    Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis.
    J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-024-04906.
    PubMed     Abstract available


  235. REDDY SC, Mao Y, Gendreau J, Ahmed AK, et al
    Clinical predictors of overall survival in very elderly meningioma patients: a surveillance, epidemiology, and end results (SEER) database analysis.
    J Neurooncol. 2025 Feb 28. doi: 10.1007/s11060-025-04982.
    PubMed     Abstract available


  236. KOSANAM AR, Ma J, White AJ, Murayi R, et al
    Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis.
    J Neurooncol. 2025 Feb 25. doi: 10.1007/s11060-025-04980.
    PubMed     Abstract available


  237. KARSY M, Kshettry VR, Little AS
    RAPID, a multicenter collaboration for the study of craniopharyngiomas: challenges, opportunities, and future directions.
    J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04981.
    PubMed    


  238. ZHU J, Wang T, Liu X, Lu T, et al
    Overexpression of LSR suppresses glioma proliferation and invasion via regulating FOXO3a.
    J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04976.
    PubMed     Abstract available


  239. WACH J, Vychopen M, Guresir E
    Prognostic revalidation of RANO categories for extent of resection in glioblastoma: a reconstruction of individual patient data.
    J Neurooncol. 2025 Feb 24. doi: 10.1007/s11060-025-04950.
    PubMed     Abstract available



  240. Correction to: Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study.
    J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-024-04924.
    PubMed    


  241. DAMANTE M, Cua S, Kreatsoulas D, Giglio P, et al
    Papillary craniopharyngioma management in the era of BRAF and MEK inhibition.
    J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-025-04969.
    PubMed     Abstract available


  242. VAN DER WEIDE HL, Buunk AM, Siebenga FF, Langendijk JA, et al
    Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study.
    J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-025-04973.
    PubMed     Abstract available


  243. DUBE CJ, Lai M, Zhang Y, Saha S, et al
    T-type calcium channels regulate medulloblastoma and can be targeted for therapy.
    J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04967.
    PubMed     Abstract available


  244. BALAGUER-LLUNA L, Olaciregui NG, Aschero R, Resa-Pares C, et al
    Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.
    J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04954.
    PubMed     Abstract available


  245. GAL O, Mehta MP, Kotecha R
    The role of upfront radiation therapy for brain metastases in the era of CNS-active systemic therapies: a narrative review of clinical trial design and lessons learned.
    J Neurooncol. 2025 Feb 17. doi: 10.1007/s11060-025-04970.
    PubMed     Abstract available


  246. ZHU X, Yuan F, Sun Q, Yang C, et al
    N-acetylcysteine remodels the tumor microenvironment of primary and recurrent mouse glioblastoma.
    J Neurooncol. 2025 Feb 15. doi: 10.1007/s11060-025-04971.
    PubMed     Abstract available


  247. LIU J, Guo S, Li Q, Yang L, et al
    Correction to: Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.
    J Neurooncol. 2025 Feb 14. doi: 10.1007/s11060-025-04960.
    PubMed    


  248. STEC NE, Barker FG 2nd, Brastianos PK
    Targeted treatment for craniopharyngioma.
    J Neurooncol. 2025 Feb 14. doi: 10.1007/s11060-025-04942.
    PubMed     Abstract available


  249. ONG CV, Samlowski W
    Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.
    J Neurooncol. 2025 Feb 11. doi: 10.1007/s11060-025-04951.
    PubMed     Abstract available


  250. WASILEWSKI D, Eitner C, Ates R, Murad S, et al
    Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charite LMD registry.
    J Neurooncol. 2025 Feb 11. doi: 10.1007/s11060-025-04937.
    PubMed     Abstract available


  251. SAKURADA K, Sato I, Ikeda M, Narita Y, et al
    Mental health status and associated factors of caregivers of patients with malignant brain tumors.
    J Neurooncol. 2025 Feb 7. doi: 10.1007/s11060-025-04963.
    PubMed     Abstract available


  252. JESSURUN CAC, Siddi F, Nawabi NLA, Hulsbergen AFC, et al
    Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.
    J Neurooncol. 2025 Feb 7. doi: 10.1007/s11060-025-04955.
    PubMed     Abstract available


  253. VIOZZI I, Hannink G, Ardon H, Balvers RK, et al
    Between-hospital variation in biopsy indication for patients with newly diagnosed glioblastoma in the Dutch Quality Registry for Neurosurgery.
    J Neurooncol. 2025 Feb 6. doi: 10.1007/s11060-025-04959.
    PubMed     Abstract available


  254. PHAM J, Cote DJ, Kang K, Briggs RG, et al
    Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database.
    J Neurooncol. 2025 Feb 5. doi: 10.1007/s11060-025-04952.
    PubMed     Abstract available


  255. STUMMER W, Gerwing M, Bilgin SS, Thomas C, et al
    Sonodynamic therapy with a single neoadjuvant, diffuse delivery of low-intensity ultrasound with 5-ALA in treatment naive glioblastoma results in tumor-specific cytotoxic edema and increased apoptosis.
    J Neurooncol. 2025 Feb 4. doi: 10.1007/s11060-025-04957.
    PubMed     Abstract available


  256. SHEEHAN JP
    Brain metastases from small cell lung cancer: focal therapies improve outcomes in the contemporary era.
    J Neurooncol. 2025 Feb 4. doi: 10.1007/s11060-025-04943.
    PubMed    


  257. JANI JA, Cowan D, Ouonkap L, Adesina D, et al
    Missing the message to brain tumor patients: a 2023 twitter analysis among patients, informal caregivers, and healthcare professionals in glioblastoma multiforme.
    J Neurooncol. 2025 Feb 3. doi: 10.1007/s11060-025-04948.
    PubMed     Abstract available


  258. LESHA E, Roach JT, Miller LE, Nichols CS, et al
    Length of stay following elective craniotomy for tumor resection in children and young adults: a retrospective case series.
    J Neurooncol. 2025;171:651-658.
    PubMed     Abstract available


  259. RODRIGUEZ B, Rivera D, Zhang JY, Brown C, et al
    Innovations in intraoperative therapies in neurosurgical oncology: a narrative review.
    J Neurooncol. 2025;171:549-557.
    PubMed     Abstract available


    January 2025
  260. HUANG JY, Yeh TC, Liu HC, Hou JY, et al
    Computerized assessment of neuropsychological functioning in pediatric brain tumor patients.
    J Neurooncol. 2025 Jan 31. doi: 10.1007/s11060-025-04945.
    PubMed     Abstract available


  261. PETERSON RK, Choi JH, King TZ
    Demographic, medical, and neighborhood barriers to clinical neuropsychological services in pediatric medulloblastoma patients treated in the United States.
    J Neurooncol. 2025 Jan 28. doi: 10.1007/s11060-025-04940.
    PubMed     Abstract available


  262. ROSENSTOCK T, Picht T, Engelhardt M, Grittner U, et al
    Improving postsurgical paresis in brain tumor patients by transcranial magnetic stimulation.
    J Neurooncol. 2025 Jan 23. doi: 10.1007/s11060-024-04931.
    PubMed     Abstract available


  263. UMEDA T, Otani Y, Fujii K, Ishida J, et al
    Identification of factors related to functional prognoses in craniopharyngiomas.
    J Neurooncol. 2025 Jan 22. doi: 10.1007/s11060-024-04925.
    PubMed     Abstract available


  264. NAHLS NS, Anttonen A, Nuutinen M, Saarto T, et al
    The impact of palliative care contact on the use of hospital resources at the end of life for brain tumor patients; a nationwide register-based cohort study.
    J Neurooncol. 2025 Jan 20. doi: 10.1007/s11060-025-04939.
    PubMed     Abstract available


  265. YAKUBOV R, Kaloti R, Persaud P, McCracken A, et al
    It's all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma.
    J Neurooncol. 2025 Jan 16. doi: 10.1007/s11060-024-04930.
    PubMed     Abstract available


  266. ZHONG S, Zuo J, Fu X, Wu C, et al
    Leptomeningeal dissemination in H3 K27M- mutant diffuse midline gliomas: clinical characteristics, risk factors, and prognostic insights.
    J Neurooncol. 2025 Jan 15. doi: 10.1007/s11060-024-04933.
    PubMed     Abstract available


  267. REDJAL N, Ziu M, Choi S, Ng PR, et al
    Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.
    J Neurooncol. 2025 Jan 13. doi: 10.1007/s11060-024-04871.
    PubMed     Abstract available


  268. WACH J, Vychopen M, Basaran AE, Tatagiba M, et al
    Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis.
    J Neurooncol. 2025 Jan 9. doi: 10.1007/s11060-024-04917.
    PubMed     Abstract available


  269. TINI P, Donnini F, Minniti G
    Refining target delineation strategies for multifocal glioblastoma: a step towards personalized radiotherapy.
    J Neurooncol. 2025 Jan 7. doi: 10.1007/s11060-024-04926.
    PubMed    


  270. NARSINH KH, Kumar K, Bankiewicz K, Martin AJ, et al
    A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.
    J Neurooncol. 2025 Jan 6. doi: 10.1007/s11060-024-04904.
    PubMed     Abstract available


  271. WU Y, Chen Z, Shi M, Qiu S, et al
    Nimotuzumab and bevacizumab combined with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme: a retrospective single-arm study.
    J Neurooncol. 2025 Jan 6. doi: 10.1007/s11060-024-04932.
    PubMed     Abstract available


  272. KAZEMI F, Gendreau JL, Parker M, Chakravarti S, et al
    Creating a predictive model and online calculator for high-value care outcomes following glioblastoma resection: incorporating neighborhood socioeconomic status index.
    J Neurooncol. 2025 Jan 4. doi: 10.1007/s11060-024-04927.
    PubMed     Abstract available


  273. DAI Q, Wei J, Li Z, Li T, et al
    Mifepristone achieves tumor suppression and ferroptosis through PR/p53/HO1/GPX4 axis in meningioma cells.
    J Neurooncol. 2025 Jan 3. doi: 10.1007/s11060-024-04918.
    PubMed     Abstract available


  274. MIAO Y, Wu D, Li Y, Ji Y, et al
    Radiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis.
    J Neurooncol. 2025 Jan 3. doi: 10.1007/s11060-024-04914.
    PubMed     Abstract available


  275. MANDELBERG N, Hodges TR, Wang TJC, McGranahan T, et al
    Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update.
    J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04898.
    PubMed     Abstract available


  276. LIM S, Clarke NH, Maloney SL, Sener UT, et al
    Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.
    J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04916.
    PubMed     Abstract available


  277. SHOSHAN Y, Gomori MJ, Moss L, Bari SE, et al
    Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors.
    J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04919.
    PubMed     Abstract available


  278. RANDRIAN V, Portales F, Bouche O, Thezenas S, et al
    The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors.
    J Neurooncol. 2025 Jan 2. doi: 10.1007/s11060-024-04905.
    PubMed     Abstract available


  279. MAROUFI SF, Maroufi SP, Fallahi MS, Sheehan JP, et al
    Long-term trends of publications in journal of neuro-oncology: a bibliographic study of a core journal in the field of neuro-oncology.
    J Neurooncol. 2025;171:329-341.
    PubMed     Abstract available


  280. KIM I, Yan M, Sourour M, Heaton R, et al
    Pituitary neuroendocrine tumors treated with stereotactic radiosurgery.
    J Neurooncol. 2025;171:423-430.
    PubMed     Abstract available


  281. ROMANOVA E, Deviaterikova A, Tolchennikova V, Karelin A, et al
    Short-term sensorimotor training incorporating cognitive tasks for pediatric survivors of posterior fossa tumors: a pilot study.
    J Neurooncol. 2025;171:393-402.
    PubMed     Abstract available


  282. KLEIN BR, Levi DJ, Shah AH, Ivan ME, et al
    Social media "SoMe" in neuro-oncology: a review of the literature.
    J Neurooncol. 2025;171:11-19.
    PubMed     Abstract available


  283. RINCON-TORROELLA J, Rakovec M, Kalluri AL, Jiang K, et al
    Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
    J Neurooncol. 2025;171:35-45.
    PubMed     Abstract available


  284. PAHWA B, Singh G, Kale SS
    The 4S of spinal astrocytoma: specific location, syrinx, spasticity and score on Modified Mccormick Scale (MMS) predict long term outcomes in patients undergoing surgical resection of intramedullary spinal astrocytomas.
    J Neurooncol. 2025;171:131-138.
    PubMed     Abstract available


  285. LIM-FAT MJ, Roberto K, Wen PY
    Clinical trial design for novel targeted agents in neuro-oncology.
    J Neurooncol. 2025;171:21-33.
    PubMed     Abstract available


    December 2024
  286. BANGASH AH, Poudel P, Alshuqayfi KM, Ahmed M, et al
    Treatment-induced ripple effect: a systematic review exploring the abscopal phenomenon in Glioblastoma multiforme.
    J Neurooncol. 2024 Dec 19. doi: 10.1007/s11060-024-04912.
    PubMed     Abstract available


  287. GREWAL EP, Nahed BV, Carter BS, Gerstner ER, et al
    Clinical progress in the development of CAR T cells to treat malignant glioma.
    J Neurooncol. 2024 Dec 18. doi: 10.1007/s11060-024-04909.
    PubMed     Abstract available


  288. CHEN H, Tan G, Zhong L, Hu Y, et al
    MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy - a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis.
    J Neurooncol. 2024 Dec 17. doi: 10.1007/s11060-024-04910.
    PubMed     Abstract available


  289. BARRAGAN-PEREZ EJ, Alvarez-Amado DE, Dies-Suarez P, Tobon SH, et al
    Retraction Note: Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience.
    J Neurooncol. 2024 Dec 16. doi: 10.1007/s11060-024-04915.
    PubMed    


  290. OBARA T, Blonski M, Forest-Dodelin M, Rech F, et al
    Health-related quality of life in 62 patients with diffuse low-grade glioma during a non-therapeutic and progression-free phase: a cross-sectional study.
    J Neurooncol. 2024 Dec 16. doi: 10.1007/s11060-024-04888.
    PubMed     Abstract available


  291. TAORI S, Habib A, Adida S, Gecici NN, et al
    Circulating biomarkers in high-grade gliomas: current insights and future perspectives.
    J Neurooncol. 2024 Dec 13. doi: 10.1007/s11060-024-04903.
    PubMed     Abstract available


  292. MONDIA MWL, Hooks RE, Maragkos GA, Smith VL, et al
    Primary diffuse leptomeningeal glioblastoma: a case report and literature review.
    J Neurooncol. 2024 Dec 12. doi: 10.1007/s11060-024-04908.
    PubMed     Abstract available


  293. MARWAHA AS, Liang Y, Shepard MJ, Yu A, et al
    Patterns of failure after stereotactic radiosurgery for brain metastases from small cell lung cancer: outcomes in the immunotherapy era.
    J Neurooncol. 2024 Dec 7. doi: 10.1007/s11060-024-04895.
    PubMed     Abstract available


  294. MOTAMED-SANAYE A, Mortezaei A, Afshari AR, Saadatian Z, et al
    Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials.
    J Neurooncol. 2024 Dec 5. doi: 10.1007/s11060-024-04865.
    PubMed     Abstract available


  295. WASILEWSKI D, Araceli T, Bischoff P, Fruh A, et al
    TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression.
    J Neurooncol. 2024 Dec 4. doi: 10.1007/s11060-024-04885.
    PubMed     Abstract available


  296. ZHEN J, Chen L, Wang H, Li D, et al
    Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence.
    J Neurooncol. 2024;170:665-673.
    PubMed     Abstract available


  297. YANG W, Chai X, Zhang N, Zhi Z, et al
    Predicting cerebellar mutism syndrome in children using lesion map combined with clinical features.
    J Neurooncol. 2024;170:591-599.
    PubMed     Abstract available


  298. BADARY A, Kertam A, El-Ramly TA, Abomera NE, et al
    Understanding metastatic involvement of the conus medullaris: a systematic review of clinical presentations, diagnostic approaches, treatment options, and patient outcomes.
    J Neurooncol. 2024;170:495-507.
    PubMed     Abstract available


    November 2024
  299. LIU Y, Cai L, Wang H, Yao L, et al
    BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression.
    J Neurooncol. 2024 Nov 28. doi: 10.1007/s11060-024-04889.
    PubMed     Abstract available


  300. SHABO E, Potthoff AL, Zeyen T, Layer JP, et al
    Transient and permanent hydrocephalus following resection of brain metastases located in the posterior fossa: incidence, risk factors and the necessity of perioperative external ventricular drainage placement.
    J Neurooncol. 2024 Nov 28. doi: 10.1007/s11060-024-04890.
    PubMed     Abstract available


  301. DEVARAJAN A, Seah C, Zhang JY, Vasan V, et al
    A four-hit mechanism is sufficient for meningioma development.
    J Neurooncol. 2024 Nov 25. doi: 10.1007/s11060-024-04877.
    PubMed     Abstract available


  302. BHARDWAJ S, Sanjay, Yadav AK
    Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells.
    J Neurooncol. 2024 Nov 25. doi: 10.1007/s11060-024-04831.
    PubMed     Abstract available


  303. HERMELO I, Haapala I, Makela M, Jacome Sanz D, et al
    Patient-derived glioma organoids real time identification of IDH mutation, 1p/19q-codeletion and CDKN2A/B homozygous deletion with differential ion mobility spectrometry.
    J Neurooncol. 2024 Nov 23. doi: 10.1007/s11060-024-04891.
    PubMed     Abstract available


  304. BADANI A, Ozair A, Khasraw M, Woodworth GF, et al
    Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
    J Neurooncol. 2024 Nov 21. doi: 10.1007/s11060-024-04881.
    PubMed     Abstract available


  305. ZIU M, Halasz LM, Kumthekar PU, McGranahan TM, et al
    Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.
    J Neurooncol. 2024 Nov 20. doi: 10.1007/s11060-024-04861.
    PubMed     Abstract available


  306. SUERO MOLINA E, Azemi G, Ozdemir Z, Russo C, et al
    Predicting intraoperative 5-ALA-induced tumor fluorescence via MRI and deep learning in gliomas with radiographic lower-grade characteristics.
    J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04875.
    PubMed     Abstract available


  307. KRENZLIN H, Jankovic D, Dauth A, Lange F, et al
    Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.
    J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04810.
    PubMed     Abstract available


  308. TANG L, Chakravarti S, Li E, Mao Y, et al
    Optimal treatment regimen for very elderly patients with atypical meningioma: an analysis of survival outcomes using the National Cancer Database (NCDB).
    J Neurooncol. 2024 Nov 19. doi: 10.1007/s11060-024-04886.
    PubMed     Abstract available


  309. VAN OPIJNEN MP, Sadigh Y, Dijkstra ME, Young JS, et al
    The impact of intraoperative mapping during re-resection in recurrent gliomas: a systematic review.
    J Neurooncol. 2024 Nov 18. doi: 10.1007/s11060-024-04874.
    PubMed     Abstract available


  310. PULCINI S, Beaussire-Trouvay L, Marguet F, Viailly PJ, et al
    The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort.
    J Neurooncol. 2024 Nov 16. doi: 10.1007/s11060-024-04879.
    PubMed     Abstract available


  311. WANG B, Bukowski A, Kaidar-Person O, Choi JM, et al
    Association between tumor location and toxicity outcomes after stereotactic radiosurgery for brain metastases.
    J Neurooncol. 2024 Nov 15. doi: 10.1007/s11060-024-04866.
    PubMed     Abstract available


  312. HERR S, Kite T, Vyas P, Karlovits S, et al
    The 5-factor modified frailty index as a prognostic factor for stereotactic radiosurgery in meningioma management.
    J Neurooncol. 2024 Nov 14. doi: 10.1007/s11060-024-04873.
    PubMed     Abstract available


  313. TINI P, Cinelli E, Yavorska M, Donnini F, et al
    Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol.
    J Neurooncol. 2024 Nov 14. doi: 10.1007/s11060-024-04862.
    PubMed     Abstract available


  314. PETITT JC, Murayi R, El-Abtah ME, Momin A, et al
    Outcomes of adjuvant radiation treatment following subtotal resection of world health organization grade II meningiomas.
    J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04878.
    PubMed     Abstract available


  315. SABAHI M, Fathi Jouzdani A, Sadeghian Z, Dabbagh Ohadi MA, et al
    CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws.
    J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04876.
    PubMed     Abstract available


  316. MOKOENA X, Mabeta P, Cordier W, Flepisi BT, et al
    Glioblastoma cells alter brain endothelial cell homeostasis and tight junction protein expression in vitro.
    J Neurooncol. 2024 Nov 13. doi: 10.1007/s11060-024-04870.
    PubMed     Abstract available


  317. KALLURI AL, Lee JH, Lucas CG, Rincon-Torroella J, et al
    Implications of molecular classifications in glioma surgery.
    J Neurooncol. 2024 Nov 12. doi: 10.1007/s11060-024-04883.
    PubMed     Abstract available


  318. EL-HAJJ VG, Ranganathan S, Hoang H, Ghaith AK, et al
    The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis.
    J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04880.
    PubMed     Abstract available


  319. IRSHAD HA, Rizvi SBA, Bajwa MH, Khalid MU, et al
    Epidemiology of glioblastoma in Pakistan: a secondary analysis of the Pakistan Brain Tumor Epidemiology Study (PBTES).
    J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04872.
    PubMed     Abstract available


  320. LAWRENCE LSP, Maralani PJ, Das S, Sahgal A, et al
    Magnetic resonance imaging techniques for monitoring glioma response to chemoradiotherapy.
    J Neurooncol. 2024 Nov 11. doi: 10.1007/s11060-024-04856.
    PubMed     Abstract available


  321. FAN Z, Gao A, Zhang J, Meng X, et al
    Study of prediction model for high-grade meningioma using fractal geometry combined with radiological features.
    J Neurooncol. 2024 Nov 4. doi: 10.1007/s11060-024-04867.
    PubMed     Abstract available


  322. BAIG MIRZA A, Fayez F, Rashed S, Burn L, et al
    Ethnicity in neuro-oncology research: How are we doing and how can we do better?
    J Neurooncol. 2024;170:223-233.
    PubMed     Abstract available


  323. ROSE ML, Moen E, Ager B, Bajaj B, et al
    Radiotherapy dosing in intracranial ependymoma using the national cancer database.
    J Neurooncol. 2024;170:387-395.
    PubMed     Abstract available


    October 2024
  324. CHEN L, Rizk E, Sherief M, Chang M, et al
    Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.
    J Neurooncol. 2024 Oct 30. doi: 10.1007/s11060-024-04859.
    PubMed     Abstract available


  325. ZHANG P, Li C, Wang Y, Chi X, et al
    Expression features of targets for anti-glioma CAR-T cell immunotherapy.
    J Neurooncol. 2024 Oct 28. doi: 10.1007/s11060-024-04855.
    PubMed     Abstract available


  326. CACCIOTTI C, Tabori U, Hawkins C, Bennett J, et al
    Targeting the RAS/MAPK pathway in children with glioma.
    J Neurooncol. 2024 Oct 25. doi: 10.1007/s11060-024-04857.
    PubMed     Abstract available


  327. WON YK, Kim ES, Jo IY, Oh HJ, et al
    Comparative analysis of hypofractionated short-course versus standard radiation therapy in elderly patients with glioblastoma: analysis of nationwide database.
    J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04853.
    PubMed     Abstract available


  328. PHAM DQ, Sheehan DE, Sheehan KA, Katsos K, et al
    Quality of life after stereotactic radiosurgery for brain metastasis: an assessment from a prospective national registry.
    J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04854.
    PubMed     Abstract available


  329. WETZEL EA, Nohman AI, Hsieh AL, Reuss D, et al
    A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.
    J Neurooncol. 2024 Oct 21. doi: 10.1007/s11060-024-04852.
    PubMed     Abstract available


  330. MADHUGIRI VS, Prasad D
    Early experience with an artificial intelligence-based module for brain metastasis detection and segmentation.
    J Neurooncol. 2024 Oct 18. doi: 10.1007/s11060-024-04851.
    PubMed     Abstract available


  331. TERRELL D, Camarano J, Whipple S, Guthikonda B, et al
    Financial toxicity in patients with glioblastoma.
    J Neurooncol. 2024 Oct 16. doi: 10.1007/s11060-024-04835.
    PubMed     Abstract available


  332. ARMOCIDA D, Bianconi A, Zancana G, Jiang T, et al
    DTI fiber-tracking parameters adjacent to gliomas: the role of tract irregularity value in operative planning, resection, and outcome.
    J Neurooncol. 2024 Oct 15. doi: 10.1007/s11060-024-04848.
    PubMed     Abstract available


  333. GARDNER MM, Winter SF, Stahl F, Gerstner ER, et al
    Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas.
    J Neurooncol. 2024 Oct 14. doi: 10.1007/s11060-024-04850.
    PubMed     Abstract available


  334. MORROW K, Sloan A, Olson JJ, Ormond DR, et al
    Congress of Neurological Surgeons systematic review and evidence?based guidelines on the management of recurrent diffuse low-grade glioma: update.
    J Neurooncol. 2024 Oct 14. doi: 10.1007/s11060-024-04838.
    PubMed     Abstract available


  335. KAMP MA, Fink L, Forster MT, Weiss Lucas C, et al
    In-patient neurosurgical tumor treatments for malignant glioma patients in Germany.
    J Neurooncol. 2024 Oct 10. doi: 10.1007/s11060-024-04784.
    PubMed     Abstract available


  336. GRIESSMAIR M, Schramm S, Ziegenfeuter J, Canisius J, et al
    Advanced imaging reveals enhanced malignancy in glioblastomas involving the subventricular zone: evidence of increased infiltrative growth and perfusion.
    J Neurooncol. 2024 Oct 10. doi: 10.1007/s11060-024-04849.
    PubMed     Abstract available


  337. YAMANISHI S, Nagashima H, Tanaka K, Uno T, et al
    Association of preoperative seizures with reduced expression of soluble CD163, an M2 macrophage marker, in the cerebrospinal fluid in isocitrate dehydrogenase wild-type glioblastoma.
    J Neurooncol. 2024 Oct 8. doi: 10.1007/s11060-024-04837.
    PubMed     Abstract available


  338. PROVLOTSKAYA I, Minnigulova A, Zyryanov A, Takmakov M, et al
    How well can simple clinical features predict long-term language recovery after left-hemisphere glioma surgery?
    J Neurooncol. 2024 Oct 6. doi: 10.1007/s11060-024-04836.
    PubMed     Abstract available


  339. FAN KY, Jerzak KJ, Kumar S, Moravan V, et al
    Predictors of brain metastases in patients with oligometastatic solid tumours treated with stereotactic body radiation therapy.
    J Neurooncol. 2024 Oct 4. doi: 10.1007/s11060-024-04834.
    PubMed     Abstract available


  340. NIEDER C, Aanes SG, Stanisavljevic L, Mannsaker B, et al
    Return to work in younger patients with brain metastases who survived for 2 years or more.
    J Neurooncol. 2024 Oct 1. doi: 10.1007/s11060-024-04840.
    PubMed     Abstract available


  341. YOUNG CC, Kan P, Chen SR, Lang FF, et al
    Endovascular surgical neuro-oncology: advancing a new subspecialty.
    J Neurooncol. 2024;170:31-40.
    PubMed     Abstract available


  342. GOMES FC, Ferreira MY, Larcipretti ALL, Freitas BCB, et al
    Sodium fluorescein and 5-aminolevulinic acid fluorescence- guided biopsy in brain lesions: a systematic review and meta-analysis.
    J Neurooncol. 2024;170:11-29.
    PubMed     Abstract available


  343. ZHAO S, Ni K, Xie J, Cheng C, et al
    Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM.
    J Neurooncol. 2024;170:101-117.
    PubMed     Abstract available


  344. KANAMORI M, Mugikura S, Iizuka O, Mori N, et al
    Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up.
    J Neurooncol. 2024;170:173-184.
    PubMed     Abstract available


  345. ROGAWSKI D, Cao T, Ma Q, Roy-O'Reilly M, et al
    Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    J Neurooncol. 2024;170:209-217.
    PubMed     Abstract available


    September 2024
  346. YAVORSKA M, Tomaciello M, Sciurti A, Cinelli E, et al
    Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.
    J Neurooncol. 2024 Sep 27. doi: 10.1007/s11060-024-04832.
    PubMed    


  347. OHNO M, Takahashi M, Yanagisawa S, Osawa S, et al
    Correction to: Development of a scoring system to predict local recurrence in brain metastases following complete resection and observation.
    J Neurooncol. 2024 Sep 25. doi: 10.1007/s11060-024-04822.
    PubMed    


  348. ZHU K, Li S, Yao H, Hei J, et al
    Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-beta/Smad signal pathway.
    J Neurooncol. 2024 Sep 25. doi: 10.1007/s11060-024-04797.
    PubMed     Abstract available


  349. KATZENDOBLER S, Niedermeyer S, Blobner J, Trumm C, et al
    Determinants of long-term survival in patients with IDH-mutant gliomas.
    J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04826.
    PubMed     Abstract available


  350. LAVIV Y, Regev O, Kanner AA, Fichman S, et al
    Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients.
    J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04828.
    PubMed     Abstract available


  351. AARONSON DM, Laing B, Singhal I, Boerger TF, et al
    Survival implications of postoperative restricted diffusion in high-grade glioma and limitations of intraoperative MRI detection.
    J Neurooncol. 2024 Sep 24. doi: 10.1007/s11060-024-04767.
    PubMed     Abstract available


  352. LANDRY AP, Yefet LS, Wang JZ, Zadeh G, et al
    Methylation profiling in the contemporary management of meningioma.
    J Neurooncol. 2024 Sep 22. doi: 10.1007/s11060-024-04825.
    PubMed     Abstract available


  353. GAL O, Mehta MP, Kotecha R
    Radiotherapeutic advances in the management of glioblastoma.
    J Neurooncol. 2024 Sep 13. doi: 10.1007/s11060-024-04824.
    PubMed     Abstract available


  354. HAN JS, Wenger T, Demetriou AN, Dallas J, et al
    Procedural volume is linearly associated with mortality, major complications, and readmissions in patients undergoing malignant brain tumor resection.
    J Neurooncol. 2024 Sep 12. doi: 10.1007/s11060-024-04800.
    PubMed     Abstract available


  355. YAVORSKA M, Tomiciello M, Antonio S, Cinelli E, et al
    Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.
    J Neurooncol. 2024 Sep 11. doi: 10.1007/s11060-024-04818.
    PubMed     Abstract available


  356. NANDOLIYA KR, Congivaram H, Youngblood MW, Chen WC, et al
    Clinical and methylomic features of spinal meningiomas.
    J Neurooncol. 2024 Sep 10. doi: 10.1007/s11060-024-04736.
    PubMed     Abstract available


  357. BASARAN AE, Arlt F, Guresir E, Vychopen M, et al
    Sexual dysfunction after surgery for primary sporadic cranial meningiomas: prevalence and risk factors.
    J Neurooncol. 2024 Sep 10. doi: 10.1007/s11060-024-04817.
    PubMed     Abstract available


  358. BARONE TA, Robinson DL, Qiu J, Gurova KV, et al
    FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair.
    J Neurooncol. 2024 Sep 9. doi: 10.1007/s11060-024-04819.
    PubMed     Abstract available


  359. PALAVANI LB, Mitre LP, Camerotte R, Nogueira BV, et al
    Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
    J Neurooncol. 2024 Sep 4. doi: 10.1007/s11060-024-04813.
    PubMed     Abstract available


  360. SCHWARTZ C, Ueberschaer MF, Rautalin I, Grauvogel J, et al
    Frailty indices predict mortality, complications and functional improvements in supratentorial meningioma patients over 80 years of age.
    J Neurooncol. 2024 Sep 4. doi: 10.1007/s11060-024-04780.
    PubMed     Abstract available


  361. DONG J, Chen Q, Weng S, Liu L, et al
    The effect of depression and anxiety on survival in patients with glioma: a systematic review and meta-analysis.
    J Neurooncol. 2024 Sep 3. doi: 10.1007/s11060-024-04799.
    PubMed     Abstract available


  362. EMINOVIC S, Orth T, Dell'Orco A, Baumgartner L, et al
    Clinical and imaging manifestations of intracerebral hemorrhage in brain tumors and metastatic lesions: a comprehensive overview.
    J Neurooncol. 2024 Sep 2. doi: 10.1007/s11060-024-04811.
    PubMed     Abstract available


  363. LANDRY AP, Zuccato JA, Patil V, Voisin MR, et al
    Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours.
    J Neurooncol. 2024;169:233-239.
    PubMed     Abstract available


  364. SHEEHAN JP, Lee CC, Fadul CE
    Progression versus pseudoprogression: radiological differentiation with contrast clearance analysis on brain MRI.
    J Neurooncol. 2024;169:695-696.
    PubMed    


  365. GHEZZI C, Ellingson BM, Lai A, Liu J, et al
    Effect of Jardiance on glucose uptake into astrocytomas.
    J Neurooncol. 2024;169:437-444.
    PubMed     Abstract available


  366. OZONO I, Onishi S, Yonezawa U, Taguchi A, et al
    Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.
    J Neurooncol. 2024;169:571-579.
    PubMed     Abstract available


  367. BAKER CR, Pease M, Sexton DP, Abumoussa A, et al
    Artificial intelligence innovations in neurosurgical oncology: a narrative review.
    J Neurooncol. 2024;169:489-496.
    PubMed     Abstract available


  368. AHMETI H, Kiese D, Freitag-Wolf S, Kalab M, et al
    IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas.
    J Neurooncol. 2024;169:423-435.
    PubMed     Abstract available


  369. STRACK M, Kuckelhaus J, Diebold M, Wuchter P, et al
    Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells.
    J Neurooncol. 2024;169:329-340.
    PubMed     Abstract available


  370. IVREN M, Cherkezov A, Reuss D, Haux D, et al
    Intracranial angioleiomyoma: a case series of seven patients and review of the literature.
    J Neurooncol. 2024;169:399-408.
    PubMed     Abstract available


    August 2024
  371. TANAKA T, Takei J, Sasaki H
    Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
    J Neurooncol. 2024 Aug 31. doi: 10.1007/s11060-024-04806.
    PubMed    


  372. HO VKY, Anten MM, Garst A, Bos EM, et al
    Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021).
    J Neurooncol. 2024 Aug 29. doi: 10.1007/s11060-024-04730.
    PubMed     Abstract available


  373. ZHU H, Allwin C, Bassous MG, Pouliopoulos AN, et al
    Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials.
    J Neurooncol. 2024 Aug 29. doi: 10.1007/s11060-024-04795.
    PubMed     Abstract available


  374. UCKERMANN O, Ziegler J, Meinhardt M, Richter S, et al
    Raman and autofluorescence spectroscopy for in situ identification of neoplastic tissue during surgical treatment of brain tumors.
    J Neurooncol. 2024 Aug 28. doi: 10.1007/s11060-024-04809.
    PubMed     Abstract available


  375. MATHEW-SCHMITT S, Peindl M, Neundorf P, Dandekar G, et al
    Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier.
    J Neurooncol. 2024 Aug 28. doi: 10.1007/s11060-024-04760.
    PubMed     Abstract available


  376. HAINFELLNER A, Borkovec M, Seebrecht L, Neuhauser M, et al
    Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population.
    J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04808.
    PubMed     Abstract available


  377. PIKIS S, Mantziaris G, Protopapa M, Tos SM, et al
    Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study.
    J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04775.
    PubMed     Abstract available


  378. ALCICEK S, Pilatus U, Manzhurtsev A, Weber KJ, et al
    Amino acid metabolism in glioma: in vivo MR-spectroscopic detection of alanine as a potential biomarker of poor survival in glioma patients.
    J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04803.
    PubMed     Abstract available


  379. SHAABAN A, Pham D, Tos SM, Mantziaris G, et al
    Biological effective dose as a predictor of local tumor control in stereotactic radiosurgery treated parasellar meningioma patients.
    J Neurooncol. 2024 Aug 27. doi: 10.1007/s11060-024-04804.
    PubMed     Abstract available


  380. CHEN H, Koul D, Zhang Y, Ghobadi SN, et al
    Pulsed focused ultrasound alters the proteomic profile of the tumor microenvironment in a syngeneic mouse model of glioblastoma.
    J Neurooncol. 2024 Aug 24. doi: 10.1007/s11060-024-04801.
    PubMed     Abstract available


  381. RIVERA CA, Bhatia S, Morell AA, Daggubati LC, et al
    Metabolic signatures derived from whole-brain MR-spectroscopy identify early tumor progression in high-grade gliomas using machine learning.
    J Neurooncol. 2024 Aug 24. doi: 10.1007/s11060-024-04812.
    PubMed     Abstract available


  382. ZHOU WT, Niu JH, Liao C, Ren SK, et al
    Visual deterioration outcomes following optic pathway glioma treatment: a 12-year single institution retrospective study.
    J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04802.
    PubMed     Abstract available


  383. WONG CE, Chang Y, Chen PW, Huang YT, et al
    Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis.
    J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04798.
    PubMed     Abstract available


  384. PICHARDO-ROJAS PS, Vazquez-Alva D, Alvarez-Castro JA, Flores-Patino B, et al
    Comparative effectiveness of frame-based and mask-based Gamma Knife stereotactic radiosurgery in brain metastases: A 509 patient meta-analysis.
    J Neurooncol. 2024 Aug 17. doi: 10.1007/s11060-024-04738.
    PubMed     Abstract available


  385. TSUJI S, Kudo U, Takahashi K, Nakamura S, et al
    The role of progranulin in macrophages of a glioblastoma model.
    J Neurooncol. 2024 Aug 14. doi: 10.1007/s11060-024-04793.
    PubMed     Abstract available


  386. ONISHI S, Yamasaki F, Akiyama Y, Kawahara D, et al
    Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign.
    J Neurooncol. 2024 Aug 12. doi: 10.1007/s11060-024-04794.
    PubMed     Abstract available


  387. KITE T, Shepard MJ
    Comment on "Amino-acid PET as a prognostic tool after post-stupp protocol temozolomide therapy in high-grade glioma patients".
    J Neurooncol. 2024 Aug 9. doi: 10.1007/s11060-024-04796.
    PubMed    


  388. XU H, Cao Y, Ruan J, Wang F, et al
    The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells.
    J Neurooncol. 2024 Aug 8. doi: 10.1007/s11060-024-04789.
    PubMed     Abstract available


  389. LEE M, Karschnia P, Park YW, Choi K, et al
    Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.
    J Neurooncol. 2024 Aug 8. doi: 10.1007/s11060-024-04737.
    PubMed     Abstract available


  390. WANG B, Qiu B, Deng X
    Comment on the paper: Wang B, Liu Y, Zhang J, Yin S, Liu B, Ding S, Qiu B, Deng X. Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study. J Neurooncol 167(1):12
    J Neurooncol. 2024 Aug 7. doi: 10.1007/s11060-024-04791.
    PubMed    



  391. Imaging timing after surgery for glioblastoma: an evaluation of practice in Great Britain and Ireland (INTERVAL-GB)- a multi-centre, cohort study.
    J Neurooncol. 2024 Aug 6. doi: 10.1007/s11060-024-04705.
    PubMed     Abstract available


  392. BELTRAN-BLESS AA, Alshamsan B, Jia J, Lo V, et al
    Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation- a patient and physician survey.
    J Neurooncol. 2024 Aug 6. doi: 10.1007/s11060-024-04764.
    PubMed     Abstract available


  393. RILINGER RG, Guo L, Sharma A, Volovetz J, et al
    Tumor-related epilepsy in high-grade glioma: a large series survival analysis.
    J Neurooncol. 2024 Aug 5. doi: 10.1007/s11060-024-04787.
    PubMed     Abstract available


  394. OHNO M, Takahashi M, Yanagisawa S, Osawa S, et al
    Development of a scoring system to predict local recurrence in brain metastases following complete resection and observation.
    J Neurooncol. 2024 Aug 5. doi: 10.1007/s11060-024-04790.
    PubMed     Abstract available


  395. VANHAUWAERT D, Silversmit G, Vanschoenbeek K, Coucke G, et al
    Association of hospital volume with survival but not with postoperative mortality in glioblastoma patients in Belgium.
    J Neurooncol. 2024 Aug 2. doi: 10.1007/s11060-024-04776.
    PubMed     Abstract available


  396. MRUGALA MM, Shi W, Iwomoto F, Lukas RV, et al
    Global post?marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.
    J Neurooncol. 2024;169:25-38.
    PubMed     Abstract available


  397. YU C, Xu T, Fang H, Wang X, et al
    High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.
    J Neurooncol. 2024;169:203-213.
    PubMed     Abstract available


  398. ZHANG S, Patel K, Dusenbery K, Alshreef A, et al
    Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience.
    J Neurooncol. 2024;169:11-23.
    PubMed     Abstract available


  399. SCHULZ N, Nichelli L, Schenone L, Ursu R, et al
    Primary central nervous system lymphomas in immunocompromised patients require specific response criteria.
    J Neurooncol. 2024;169:51-60.
    PubMed     Abstract available


  400. YANG Y, Wadhwani N, Shimomura A, Zheng S, et al
    Long-term outcomes of central neurocytoma - an institutional experience.
    J Neurooncol. 2024;169:195-201.
    PubMed     Abstract available


  401. RAUSCHENBACH L, Kolbe P, Engel A, Ahmadipour Y, et al
    Predictors and surgical outcome of hemorrhagic metastatic brain malignancies.
    J Neurooncol. 2024;169:165-173.
    PubMed     Abstract available


  402. YOUSEFI Y, Nejati R, Eslahi A, Alizadeh F, et al
    Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O(6)-methylguanine DNA methyltransferase (MGMT).
    J Neurooncol. 2024;169:129-135.
    PubMed     Abstract available


  403. SCHLIEPER-SCHERF S, Hebach N, Hausmann D, Azorin DD, et al
    Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models.
    J Neurooncol. 2024 Aug 1. doi: 10.1007/s11060-024-04786.
    PubMed     Abstract available


  404. KAISMAN-ELBAZ T, Blumenfeld P, Wygoda M, Feldman J, et al
    Recovery of cranial nerve neuropathies after LINAC-based stereotactic radiosurgery for benign cavernous sinus meningioma.
    J Neurooncol. 2024 Aug 1. doi: 10.1007/s11060-024-04783.
    PubMed     Abstract available


    July 2024
  405. NATSUME K, Yoshida A, Sakakima H, Yonezawa H, et al
    Age-independent benefits of postoperative rehabilitation during chemoradiotherapy on functional outcomes and survival in patients with glioblastoma.
    J Neurooncol. 2024 Jul 30. doi: 10.1007/s11060-024-04785.
    PubMed     Abstract available


  406. FERREIRA MY, Antonia O M Pereira M, Hemais M, Bocanegra-Becerra JE, et al
    Comparative efficacy and safety of sodium fluorescein-guided surgery versus standard white light for resection of brain metastases: a systematic review and meta-analysis.
    J Neurooncol. 2024 Jul 30. doi: 10.1007/s11060-024-04768.
    PubMed     Abstract available


  407. DU H, Sun J, Wang X, Zhao L, et al
    FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells.
    J Neurooncol. 2024 Jul 29. doi: 10.1007/s11060-024-04771.
    PubMed     Abstract available


  408. ASFAW ZK, Young T, Brown C, Germano IM, et al
    Charting the success of neuronavigation in brain tumor surgery: from inception to adoption and evolution.
    J Neurooncol. 2024 Jul 24. doi: 10.1007/s11060-024-04778.
    PubMed     Abstract available


  409. PANEK WK, Toedebusch RG, Mclaughlin BE, Dickinson PJ, et al
    The CCL2-CCR4 axis promotes Regulatory T cell trafficking to canine glioma tissues.
    J Neurooncol. 2024 Jul 24. doi: 10.1007/s11060-024-04766.
    PubMed     Abstract available


  410. BOCCUNI L, Roca-Ventura A, Buloz-Osorio E, Leno-Colorado D, et al
    Non-invasive prehabilitation to foster widespread fMRI cortical reorganization before brain tumor surgery: lessons from a case series.
    J Neurooncol. 2024 Jul 23. doi: 10.1007/s11060-024-04774.
    PubMed     Abstract available


  411. SCANLON SE, Shanahan RM, Bin-Alamer O, Bouras A, et al
    Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.
    J Neurooncol. 2024 Jul 23. doi: 10.1007/s11060-024-04772.
    PubMed     Abstract available


  412. FERNANDEZ-GIL BI, Schiapparelli P, Navarro-Garcia de Llano JP, Otamendi-Lopez A, et al
    Effects of PreOperative radiotherapy in a preclinical glioblastoma model: a paradigm-shift approach.
    J Neurooncol. 2024 Jul 22. doi: 10.1007/s11060-024-04765.
    PubMed     Abstract available


  413. YAMADA S, Umehara T, Sonehara K, Kijima N, et al
    Genome-wide association study on meningioma risk in Japan: a multicenter prospective study.
    J Neurooncol. 2024 Jul 13. doi: 10.1007/s11060-024-04727.
    PubMed     Abstract available


  414. KARABACAK M, Jagtiani P, Carrasquilla A, Jain A, et al
    Simplifying synthesis of the expanding glioblastoma literature: a topic modeling approach.
    J Neurooncol. 2024 Jul 11. doi: 10.1007/s11060-024-04762.
    PubMed     Abstract available


  415. PICHARDO-ROJAS PS, Pichardo-Rojas D, Marin-Castaneda LA, Palacios-Cruz M, et al
    Prognostic value of surgical resection over biopsy in elderly patients with glioblastoma: a meta-analysis.
    J Neurooncol. 2024 Jul 11. doi: 10.1007/s11060-024-04752.
    PubMed     Abstract available


  416. JEISING S, Nickel AC, Trubel J, Felsberg J, et al
    A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases.
    J Neurooncol. 2024 Jul 10. doi: 10.1007/s11060-024-04763.
    PubMed     Abstract available


  417. MAHAJAN A, Goldberg SL, Weiss SA, Tran T, et al
    Patterns of brain metastases response to immunotherapy with pembrolizumab.
    J Neurooncol. 2024 Jul 4. doi: 10.1007/s11060-024-04754.
    PubMed     Abstract available


  418. KAHL KH, Krauss PE, Neu M, Maurer CJ, et al
    Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment- update of the oncological outcome form a single center cohort after 117 procedures.
    J Neurooncol. 2024 Jul 4. doi: 10.1007/s11060-024-04691.
    PubMed     Abstract available


  419. WAGNER S, Ewald C, Freitag D, Herrmann KH, et al
    Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI.
    J Neurooncol. 2024 Jul 3. doi: 10.1007/s11060-024-04725.
    PubMed     Abstract available


  420. ZHOU J, Sun W, Li H, Song X, et al
    Application of 5T glutamate chemical exchange saturation transfer imaging in brain tumors: preliminary results.
    J Neurooncol. 2024 Jul 3. doi: 10.1007/s11060-024-04759.
    PubMed     Abstract available


  421. SHETTY A, Wang S, Khan AB, English CW, et al
    Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.
    J Neurooncol. 2024;168:515-524.
    PubMed     Abstract available


  422. TAN LF, Lim M
    Reply to "Elevating the findings by substituting in 'ISarcoPRM'".
    J Neurooncol. 2024;168:563-564.
    PubMed    


  423. DA SILVA EB JR, Ramina R, Novak Filho JL, Jung GS, et al
    Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations.
    J Neurooncol. 2024;168:555-562.
    PubMed     Abstract available


  424. MATSUDA R, Maeoka R, Morimoto T, Nakazawa T, et al
    Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator.
    J Neurooncol. 2024;168:487-494.
    PubMed     Abstract available


  425. KNOBLAUCH AL, Blass BI, Steiert C, Neidert N, et al
    Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease.
    J Neurooncol. 2024;168:537-545.
    PubMed     Abstract available


  426. COLE KL, Earl ER, Findlay MC, Sherrod BA, et al
    Assessing survival in non-small cell lung cancer brain metastases after stereotactic radiosurgery: before and after the start of the targetable mutation era.
    J Neurooncol. 2024 Jul 1. doi: 10.1007/s11060-024-04749.
    PubMed     Abstract available


    June 2024
  427. GUIDARA S, Seyve A, Poncet D, Leonce C, et al
    Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
    J Neurooncol. 2024 Jun 27. doi: 10.1007/s11060-024-04733.
    PubMed     Abstract available


  428. IANNALFI A, Riva G, Lillo S, Ciccone L, et al
    Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes.
    J Neurooncol. 2024 Jun 25. doi: 10.1007/s11060-024-04751.
    PubMed     Abstract available


  429. ERSOY TF, Brainman D, Coras R, Berger B, et al
    Defining the role of surgery for patients with multiple brain metastases.
    J Neurooncol. 2024 Jun 25. doi: 10.1007/s11060-024-04739.
    PubMed     Abstract available


  430. ROUX A, Elia A, Hudelist B, Benzakoun J, et al
    Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification.
    J Neurooncol. 2024 Jun 24. doi: 10.1007/s11060-024-04747.
    PubMed     Abstract available


  431. PARK J, Kim YJ, Lee M, Kim D, et al
    Correlation of LLT-1 and NLRC4 inflammasome and its effect on glioblastoma prognosis.
    J Neurooncol. 2024 Jun 22. doi: 10.1007/s11060-024-04750.
    PubMed     Abstract available


  432. ROUX A, Zanello M, Pallud J
    Comment on "Clinical course after Carmustine wafer implantation for newly-diagnosed adult-type diffuse gliomas; a controlled propensity matched analysis of a single center cohort".
    J Neurooncol. 2024 Jun 21. doi: 10.1007/s11060-024-04756.
    PubMed    


  433. NIEDERMEYER S, Schmutzer-Sondergeld M, Weller J, Katzendobler S, et al
    Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis.
    J Neurooncol. 2024 Jun 21. doi: 10.1007/s11060-024-04744.
    PubMed     Abstract available


  434. DECRAENE B, Coppens G, Spans L, Solie L, et al
    A novel methylation signature predicts extreme long-term survival in glioblastoma.
    J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04741.
    PubMed     Abstract available


  435. GELMERS F, Timmerman ME, Siebenga FF, van der Weide HL, et al
    Clusters of resilience and vulnerability: executive functioning, coping and mental distress in patients with diffuse low-grade glioma.
    J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04704.
    PubMed     Abstract available


  436. GOMEZ D, Feng JJ, Cheok S, Shah I, et al
    Incidence of brain metastasis according to patient race and primary cancer origin: a systematic review.
    J Neurooncol. 2024 Jun 19. doi: 10.1007/s11060-024-04748.
    PubMed     Abstract available


  437. CAI L, Liu Y, Li Y, Liu B, et al
    TRIM37 interacts with EZH2 to epigenetically suppress PTCH1 and regulate stemness in glioma stem cells through sonic hedgehog pathway.
    J Neurooncol. 2024 Jun 17. doi: 10.1007/s11060-024-04726.
    PubMed     Abstract available


  438. ZHU H, Li Y, Ding Y, Liu Y, et al
    Multi-pool chemical exchange saturation transfer MRI in glioma grading, molecular subtyping and evaluating tumor proliferation.
    J Neurooncol. 2024 Jun 14. doi: 10.1007/s11060-024-04729.
    PubMed     Abstract available


  439. JOO B, Kim JH, Ahn SG, Park M, et al
    De novo versus recurrent metastatic breast cancer affects the extent of brain metastases.
    J Neurooncol. 2024 Jun 12. doi: 10.1007/s11060-024-04735.
    PubMed     Abstract available


  440. DHARNIPRAGADA R, Shah RA, Reynolds M, Dusenbery K, et al
    Laser interstitial thermal therapy followed by consolidation stereotactic radiosurgery (LITT-cSRS) in patients with newly diagnosed brain metastasis.
    J Neurooncol. 2024 Jun 12. doi: 10.1007/s11060-024-04712.
    PubMed     Abstract available


  441. DAGHER R, Gad M, da Silva de Santana P, Sadeghi MA, et al
    Correction to: Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
    J Neurooncol. 2024 Jun 10. doi: 10.1007/s11060-024-04718.
    PubMed    


  442. ZINSZ A, Ahrari S, Becker J, Mortada A, et al
    Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
    J Neurooncol. 2024 Jun 6. doi: 10.1007/s11060-024-04722.
    PubMed     Abstract available


  443. TOYODA M, Shibahara I, Shigeeda R, Fujitani K, et al
    Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
    J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04687.
    PubMed     Abstract available


  444. KUTUK T, Zhang Y, Akdemir EY, Yarlagadda S, et al
    Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis.
    J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04706.
    PubMed     Abstract available


  445. HOCKING MC, Schultz RT, Yerys BE, Minturn JE, et al
    White matter connectivity and social functioning in survivors of pediatric brain tumor.
    J Neurooncol. 2024 Jun 5. doi: 10.1007/s11060-024-04724.
    PubMed     Abstract available


  446. PICART T, Hervey-Jumper S
    Central nervous system regulation of diffuse glioma growth and invasion: from single unit physiology to circuit remodeling.
    J Neurooncol. 2024 Jun 4. doi: 10.1007/s11060-024-04719.
    PubMed     Abstract available


  447. BRAY DP, Stubbs NM, Chow J, Jahangiri A, et al
    Frailty in patients with IDH-mutant gliomas: experience from a high-volume tumor center.
    J Neurooncol. 2024 Jun 4. doi: 10.1007/s11060-024-04685.
    PubMed     Abstract available


  448. BELLOMO J, Zeitlberger AM, Padevit L, Stumpo V, et al
    Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis.
    J Neurooncol. 2024 Jun 3. doi: 10.1007/s11060-024-04728.
    PubMed     Abstract available


  449. CAPATINA C, Hanzu FA, Hinojosa-Amaya JM, Fleseriu M, et al
    Medical treatment of functional pituitary adenomas, trials and tribulations.
    J Neurooncol. 2024;168:197-213.
    PubMed     Abstract available


  450. LAWSON MCLEAN AC, Lawson McLean A, Ernst T, Forster MT, et al
    Benchmarking palliative care practices in neurooncology: a german perspective.
    J Neurooncol. 2024;168:333-343.
    PubMed     Abstract available


  451. BIELAMOWICZ KJ, Littrell MB, Albert GW, Parker LS, et al
    Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse.
    J Neurooncol. 2024;168:367-373.
    PubMed     Abstract available


  452. YAMAMURA T, Tamura K, Kobayashi D, Inaji M, et al
    Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of (11)C-methionine in IDH-mutant astrocytoma.
    J Neurooncol. 2024;168:355-365.
    PubMed     Abstract available


  453. DUAN L, He Y, Guo W, Du Y, et al
    Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma.
    J Neurooncol. 2024;168:283-298.
    PubMed     Abstract available


    May 2024
  454. HO CH, Shieh LT, Lin CH, Guo HR, et al
    The role of adjuvant radiotherapy for intracranial malignant meningiomas: analysis of a nationwide database.
    J Neurooncol. 2024 May 30. doi: 10.1007/s11060-024-04720.
    PubMed     Abstract available


  455. LI C, Long L, Wang Y, Chi X, et al
    Constitutive type-1 interferons signaling activity in malignant gliomas.
    J Neurooncol. 2024 May 24. doi: 10.1007/s11060-024-04601.
    PubMed     Abstract available


  456. LUCKETT PH, Olufawo MO, Park KY, Lamichhane B, et al
    Predicting post-surgical functional status in high-grade glioma with resting state fMRI and machine learning.
    J Neurooncol. 2024 May 24. doi: 10.1007/s11060-024-04715.
    PubMed     Abstract available


  457. ONO T, Suzuki H, Nanjo H, Shimizu H, et al
    Clinical Course after Carmustine Wafer Implantation for Newly Diagnosed Adult-type Diffuse Gliomas; A controlled propensity matched analysis of a single center cohort.
    J Neurooncol. 2024 May 23. doi: 10.1007/s11060-024-04679.
    PubMed     Abstract available


  458. SIMON M, Kuschel LP, von Hoff K, Yuan D, et al
    Rapid DNA methylation-based classification of pediatric brain tumors from ultrasonic aspirate specimens.
    J Neurooncol. 2024 May 21. doi: 10.1007/s11060-024-04702.
    PubMed     Abstract available


  459. BLAKSTAD H, Mendoza Mireles EE, Kierulf-Vieira KS, Singireddy D, et al
    The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients.
    J Neurooncol. 2024 May 19. doi: 10.1007/s11060-024-04709.
    PubMed     Abstract available


  460. HUDELIST B, Elia A, Roux A, Paun L, et al
    Impact of frailty on survival glioblastoma, IDH-wildtype patients.
    J Neurooncol. 2024 May 19. doi: 10.1007/s11060-024-04699.
    PubMed     Abstract available


  461. DORON O, Wong T, Ablyazova F, Singha S, et al
    Correction to: Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
    J Neurooncol. 2024 May 17. doi: 10.1007/s11060-024-04701.
    PubMed    


  462. RONSLEY R, Karvonen KA, Cole B, Paulson V, et al
    Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    J Neurooncol. 2024 May 16. doi: 10.1007/s11060-024-04645.
    PubMed     Abstract available


  463. PECIU-FLORIANU I, Vannod-Michel Q, Vauleon E, Bonneterre ME, et al
    Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240).
    J Neurooncol. 2024 May 16. doi: 10.1007/s11060-024-04693.
    PubMed     Abstract available


  464. GOULENKO V, Madhugiri VS, Bregy A, Recker M, et al
    Histopathological correlation of brain tumor recurrence vs. radiation effect post-radiosurgery as detected by MRI contrast clearance analysis: a validation study.
    J Neurooncol. 2024 May 15. doi: 10.1007/s11060-024-04697.
    PubMed     Abstract available


  465. RALEIGH DR, Chen WC, Gondi V, Rogers L, et al
    Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.
    J Neurooncol. 2024 May 14. doi: 10.1007/s11060-024-04700.
    PubMed    


  466. POLETES C, Amanirad B, Santiago AT, Yan M, et al
    The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis.
    J Neurooncol. 2024 May 13. doi: 10.1007/s11060-024-04707.
    PubMed     Abstract available


  467. COVELL MM, Roy JM, Gupta N, Raihane AS, et al
    Frailty in intracranial meningioma resection: the risk analysis index demonstrates strong discrimination for predicting non-home discharge and in-hospital mortality.
    J Neurooncol. 2024 May 7. doi: 10.1007/s11060-024-04703.
    PubMed     Abstract available


  468. OTTENHAUSEN M, Renovanz M, Bartz I, Poplawski A, et al
    Use of complementary therapies and supportive measures of patients with intracranial gliomas-a prospective evaluation in an outpatient clinic.
    J Neurooncol. 2024 May 6. doi: 10.1007/s11060-024-04696.
    PubMed     Abstract available


  469. SHIN I, Sim Y, Choi SH, Park YW, et al
    Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
    J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04656.
    PubMed     Abstract available


  470. BAQRI W, Rzadki K, Habbous S, Das S, et al
    Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.
    J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04690.
    PubMed     Abstract available


  471. GECICI NN, Gurses ME, Kaye B, Jimenez NLF, et al
    Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis.
    J Neurooncol. 2024;168:1-11.
    PubMed     Abstract available


  472. FEHRENBACH MK, Wilhelmy F, Wende T, Guresir E, et al
    Perioperative psychological distress in patients with intracranial tumors; a single center study.
    J Neurooncol. 2024;168:151-157.
    PubMed     Abstract available


  473. ABDULSALAM AJ, Kara M, Ozcakar L
    Elevating the findings by substituting in "ISarcoPRM".
    J Neurooncol. 2024;168:185-186.
    PubMed    


  474. RODRIGUES AJ, Chernikova SB, Wang Y, Trinh TTH, et al
    Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
    J Neurooncol. 2024;168:125-138.
    PubMed     Abstract available


  475. WANG M, Chen M, Ge Y
    Comment on "Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control''.
    J Neurooncol. 2024;167:525.
    PubMed    


  476. KASATKIN VN, Romanova EN, Glebova EV, Deviaterikova AA, et al
    Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study.
    J Neurooncol. 2024;168:57-67.
    PubMed     Abstract available


  477. LALANCETTE E, Cantin E, Routhier ME, Mailloux C, et al
    Impact of trametinib on the neuropsychological profile of NF1 patients.
    J Neurooncol. 2024;167:447-454.
    PubMed     Abstract available


  478. BARBOUR AB, Blouw B, Taylor LP, Graber JJ, et al
    Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
    J Neurooncol. 2024;167:509-514.
    PubMed     Abstract available


  479. TONG T, Chen H, Mo C, Zhong L, et al
    Clinical characteristics and predictive factors of delayed diagnosis in patients with sellar germ cell tumors.
    J Neurooncol. 2024;167:467-476.
    PubMed     Abstract available


  480. DAVISON MA, Lilly DT, Patel AA, Kashkoush A, et al
    Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas.
    J Neurooncol. 2024;167:437-446.
    PubMed     Abstract available


  481. NAKAGAWA K, Takano K, Nishino K, Ohe S, et al
    Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
    J Neurooncol. 2024;167:397-406.
    PubMed     Abstract available


    April 2024
  482. LI G, Tian Q, Wang S, Li K, et al
    Superficial meningioma with bone involvement: surgical strategies and clinical outcomes.
    J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04604.
    PubMed     Abstract available


  483. BASREE MM, Li C, Um H, Bui AH, et al
    Leveraging radiomics and machine learning to differentiate radiation necrosis from recurrence in patients with brain metastases.
    J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04669.
    PubMed     Abstract available


  484. DORON O, Wong T, Ablyazova F, Singha S, et al
    Results from a first-in-human phase i safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
    J Neurooncol. 2024 Apr 26. doi: 10.1007/s11060-024-04647.
    PubMed     Abstract available


  485. WANG S, Zhang D, Wang J, Peng X, et al
    PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
    J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04655.
    PubMed     Abstract available


  486. PARKER M, Kazemi F, Ahmed AK, Kuo CC, et al
    Exploring the impact of primary care utilization and health information exchange upon treatment patterns and clinical outcomes of glioblastoma patients.
    J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04677.
    PubMed     Abstract available


  487. JOST J, Volker K, Brandt R, Stummer W, et al
    Correction to: Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
    J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04686.
    PubMed    


  488. MAIURI F, Corvino S, Corazzelli G, Del Basso De Caro M, et al
    Single versus multiple reoperations for recurrent intracranial meningiomas.
    J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04673.
    PubMed     Abstract available


  489. OKAMOTO T, Mizuta R, Takahashi Y, Otani Y, et al
    Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data.
    J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04628.
    PubMed     Abstract available


  490. SUN T, Liu B, Cai L, Zhou Y, et al
    Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.
    J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04689.
    PubMed     Abstract available


  491. KOIDE Y, Nagai N, Adachi S, Ito M, et al
    Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study.
    J Neurooncol. 2024 Apr 22. doi: 10.1007/s11060-024-04681.
    PubMed     Abstract available


  492. CZARNOTA GJ
    Comment in reply to Chen et al. Journal of Neuro-Oncology (2023) 165:535-545 "Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study".
    J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04675.
    PubMed    


  493. CONRAD K, Lober-Handwerker R, Hazaymeh M, Rohde V, et al
    Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.
    J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04683.
    PubMed     Abstract available


  494. DESAI J, Rajkumar S, Shepard MJ, Herbst J, et al
    National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04663.
    PubMed     Abstract available


  495. SALAME AAM, Charchar HLS, de Oliveira Dourado JP, Mendonca B, et al
    Neuroradiological features of patients with bilateral macronodular adrenocortical disease and meningiomas associated or not with genetic variants of ARMC5- a case series.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04680.
    PubMed     Abstract available


  496. MASHIACH E, Alzate JD, De Nigris Vasconcellos F, Adams S, et al
    Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04651.
    PubMed     Abstract available


  497. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04668.
    PubMed     Abstract available


  498. KOCHER D, Cao L, Guiho R, Langhammer M, et al
    Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04672.
    PubMed     Abstract available


  499. WILSON L, Atallah A, Romero JM
    Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma.
    J Neurooncol. 2024 Apr 15. doi: 10.1007/s11060-024-04666.
    PubMed    


  500. SHEEHAN JP, Trifiletti DM, Lehrer EJ
    Tissue biopsy before resection in glioblastoma: is there an opportunity to improve outcomes with liquid biopsies and pre-operative stereotactic radiosurgery?
    J Neurooncol. 2024 Apr 11. doi: 10.1007/s11060-024-04678.
    PubMed    


  501. CHEN KT, Huang CY, Pai PC, Yang WC, et al
    Correction to: Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
    J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04671.
    PubMed    


  502. KONDO N, Kinouchi T, Natsumeda M, Matsuzaki J, et al
    Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapy.
    J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04649.
    PubMed     Abstract available


  503. MIRZAYEVA L, Ucar M, Kaymaz AM, Temel E, et al
    Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.
    J Neurooncol. 2024 Apr 3. doi: 10.1007/s11060-024-04660.
    PubMed     Abstract available


  504. MAHMOODIFAR S, Pangal DJ, Neman J, Zada G, et al
    Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04630.
    PubMed     Abstract available


  505. DMUKAUSKAS M, Cioffi G, Waite KA, Sloan AE, et al
    Sex differences in adverse events in Medicare individuals >/= 66 years of age post glioblastoma treatment.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04652.
    PubMed     Abstract available


  506. LU VM, Brun JD, Niazi TN, Brun JD, et al
    Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04664.
    PubMed     Abstract available


  507. XIANG Y, Chen Y, Xu Z, Zhou S, et al
    Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04662.
    PubMed     Abstract available


  508. JOST J, Volker K, Brandt R, Stummer W, et al
    Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
    J Neurooncol. 2024 Apr 1. doi: 10.1007/s11060-024-04629.
    PubMed     Abstract available


  509. ROGERS JL, Wall T, Acquaye-Mallory AA, Boris L, et al
    Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
    J Neurooncol. 2024;167:349-359.
    PubMed     Abstract available


    March 2024
  510. TONG E, Horsley P, Wheeler H, Wong M, et al
    Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    J Neurooncol. 2024 Mar 29. doi: 10.1007/s11060-024-04643.
    PubMed     Abstract available


  511. FLORES-PACO P, Vargas-Aliaga A, Guevara MG, Lopera I, et al
    A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project.
    J Neurooncol. 2024 Mar 27. doi: 10.1007/s11060-024-04618.
    PubMed     Abstract available


  512. WATANABE G, Young K, Rauber E, Khan MF, et al
    A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.
    J Neurooncol. 2024 Mar 26. doi: 10.1007/s11060-024-04659.
    PubMed     Abstract available


  513. STRAUBE C, Combs SE, Bernhardt D, Gempt J, et al
    Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
    J Neurooncol. 2024 Mar 23. doi: 10.1007/s11060-024-04633.
    PubMed     Abstract available


  514. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
    Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
    J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04635.
    PubMed    


  515. ZAKI PG, Herr S, Shepard MJ
    Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
    J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04602.
    PubMed    


  516. FINK L, van Oorschot B, von Sass C, Dibue M, et al
    Palliative care for in-patient malignant glioma patients in Germany.
    J Neurooncol. 2024 Mar 20. doi: 10.1007/s11060-024-04611.
    PubMed     Abstract available


  517. GEENS W, Vanlaer N, Nijland L, Van Laere S, et al
    Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
    J Neurooncol. 2024 Mar 19. doi: 10.1007/s11060-024-04646.
    PubMed     Abstract available


  518. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
    Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    J Neurooncol. 2024 Mar 18. doi: 10.1007/s11060-024-04641.
    PubMed    


  519. ZHU P, Pichardo-Rojas PS, Dono A, Tandon N, et al
    The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database.
    J Neurooncol. 2024 Mar 16. doi: 10.1007/s11060-024-04644.
    PubMed     Abstract available


  520. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
    Correction to: Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
    J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04640.
    PubMed    


  521. JIANG J, Li WB, Xiao SW
    Correction to: Prognostic factors analysis of diffuse midline glioma.
    J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04634.
    PubMed    


  522. PALAVANI LB, Silva GM, Borges PGLB, Ferreira MY, et al
    Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis.
    J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04621.
    PubMed     Abstract available


  523. DI NUNNO V, Lombardi G, Simonelli M, Minniti G, et al
    The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
    J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04589.
    PubMed     Abstract available


  524. GRAILLON T, Salgues B, Horowitz T, Padovani L, et al
    Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.
    J Neurooncol. 2024 Mar 7. doi: 10.1007/s11060-024-04622.
    PubMed     Abstract available


  525. SINGH E, Gurses ME, Costello MC, Berke C, et al
    Correction to: Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
    J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04619.
    PubMed    


  526. YOKOGAMI K, Watanabe T, Yamashita S, Mizuguchi A, et al
    Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma.
    J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04625.
    PubMed     Abstract available


  527. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
    Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
    J Neurooncol. 2024 Mar 4. doi: 10.1007/s11060-024-04627.
    PubMed     Abstract available


  528. LIM MJR, Zhang Z, Zheng Y, Khoo IWL, et al
    Effect of sarcopenia and frailty on outcomes among patients with brain metastases.
    J Neurooncol. 2024 Mar 2. doi: 10.1007/s11060-023-04542.
    PubMed     Abstract available


  529. CHEN Y, Ning J, Shu L, Wen L, et al
    CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
    J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-023-04548.
    PubMed     Abstract available


  530. KEGOYA Y, Otani Y, Inoue Y, Mizuta R, et al
    Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
    J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-024-04587.
    PubMed     Abstract available


  531. SHEEHAN JP, Singh R, Trifiletti DM
    Stereotactic radiosurgery for intracranial adenoid cystic carcinoma.
    J Neurooncol. 2024;167:229-230.
    PubMed    


  532. WILSON JS, Main C, Thorp N, Taylor RE, et al
    The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review.
    J Neurooncol. 2024;167:1-34.
    PubMed     Abstract available


  533. RANADE M, Epari S, Shetty O, Dhanavade S, et al
    CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    J Neurooncol. 2024;167:189-198.
    PubMed     Abstract available


    February 2024
  534. YU M, Ge Y, Wang Z, Zhang Y, et al
    The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
    J Neurooncol. 2024 Feb 29. doi: 10.1007/s11060-024-04609.
    PubMed     Abstract available


  535. CEPEDA S, Garcia-Garcia S, Arrese I, Sarabia R, et al
    Non-navigated 2D intraoperative ultrasound: An unsophisticated surgical tool to achieve high standards of care in glioma surgery.
    J Neurooncol. 2024 Feb 28. doi: 10.1007/s11060-024-04614.
    PubMed     Abstract available


  536. JALLOH M, Kankam SB
    Harnessing imaging biomarkers for glioblastoma metastasis diagnosis: a correspondence.
    J Neurooncol. 2024 Feb 23. doi: 10.1007/s11060-024-04606.
    PubMed    


  537. YILMAZ MT, Kahvecioglu A, Yazici G, Mohammadipour S, et al
    Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center.
    J Neurooncol. 2024 Feb 22. doi: 10.1007/s11060-024-04607.
    PubMed     Abstract available


  538. JIANG J, Li WB, Xiao SW
    Prognostic factors analysis of diffuse midline glioma.
    J Neurooncol. 2024 Feb 21. doi: 10.1007/s11060-024-04605.
    PubMed     Abstract available


  539. EHRET F, Zuhlke O, Schweizer L, Kahn J, et al
    Validation of a methylation-based signature for subventricular zone involvement in glioblastoma.
    J Neurooncol. 2024 Feb 20. doi: 10.1007/s11060-024-04570.
    PubMed     Abstract available


  540. DASGUPTA P, Ou A, Lin H, Gregory T, et al
    The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-023-04551.
    PubMed     Abstract available


  541. BACCILI CURY MEGID T, Baskurt Z, Ma LX, Barron CC, et al
    Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04576.
    PubMed     Abstract available


  542. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
    Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04593.
    PubMed     Abstract available


  543. UMEKAWA M, Shinya Y, Hasegawa H, Morshed RA, et al
    Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 18. doi: 10.1007/s11060-023-04537.
    PubMed     Abstract available


  544. ARNOLD LM, Hoshina Y, Lee H, Colman H, et al
    Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04588.
    PubMed     Abstract available


  545. SHEEHAN JP, Mantziaris G, Bunevicius A
    Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04592.
    PubMed    


  546. SHIRAI Y, Ueno T, Kojima S, Ikeuchi H, et al
    The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04563.
    PubMed     Abstract available


  547. WASILEWSKI D, Onken J, Horicke P, Bukatz J, et al
    Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
    J Neurooncol. 2024 Feb 15. doi: 10.1007/s11060-024-04590.
    PubMed     Abstract available


  548. DONO A, Torres J, Nunez L, Arevalo O, et al
    Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04575.
    PubMed     Abstract available


  549. KOAY JM, Michaelides L, Moniz-Garcia DP, Quinones-Hinojosa A, et al
    Repeated surgical resections for management of high-grade glioma and its impact on quality of life.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04600.
    PubMed     Abstract available


  550. ANGELOVA P, Gicheva M
    Comment: Additional factors affecting cognitive function in low grade glioma patients.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04598.
    PubMed    


  551. WATANABE G, Wong JM, Estes B, Khan MF, et al
    Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
    J Neurooncol. 2024 Feb 12. doi: 10.1007/s11060-024-04584.
    PubMed     Abstract available


  552. FAIRCHILD A, Salama JK, Godfrey D, Wiggins WF, et al
    Incidence and imaging characteristics of difficult to detect retrospectively identified brain metastases in patients receiving repeat courses of stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04594.
    PubMed     Abstract available


  553. MIRIAN C, Jensen LR, Juratli TA, Maier AD, et al
    The importance of considering competing risks in recurrence analysis of intracranial meningioma.
    J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04572.
    PubMed     Abstract available


  554. ALHALABI OT, Dao Trong P, Kaes M, Jakobs M, et al
    Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
    J Neurooncol. 2024 Feb 9. doi: 10.1007/s11060-024-04595.
    PubMed     Abstract available


  555. KERIC N, Krenzlin H, Kalasauskas D, Freyschlag CF, et al
    Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04585.
    PubMed     Abstract available


  556. AVERBUCH I, Tschernichovsky R, Yust-Katz S, Rotem O, et al
    Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
    J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04562.
    PubMed     Abstract available


  557. TRAN S, Lapidus A, Neal A, Peters KB, et al
    A systematic review of the impact of brain tumours on risk of motor vehicle crashes.
    J Neurooncol. 2024 Feb 6. doi: 10.1007/s11060-024-04586.
    PubMed     Abstract available


  558. SALANS M, Ni L, Morin O, Ziemer B, et al
    Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.
    J Neurooncol. 2024 Feb 5. doi: 10.1007/s11060-024-04578.
    PubMed     Abstract available


  559. TANG JD, Mills MN, Nakashima J, Dohm AE, et al
    Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-023-04543.
    PubMed     Abstract available


  560. ZIMMERMANN MLM, Breedt LC, Centeno EGZ, Reijneveld JC, et al
    The relationship between pathological brain activity and functional network connectivity in glioma patients.
    J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-024-04577.
    PubMed     Abstract available


  561. HAMMER Y, Najjar W, Kahanov L, Joskowicz L, et al
    Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline.
    J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04580.
    PubMed     Abstract available


  562. WANG B, Liu Y, Zhang J, Yin S, et al
    Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study.
    J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04583.
    PubMed     Abstract available


  563. KHOWAL S, Zhang D, Yong WH, Heaney AP, et al
    Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas.
    J Neurooncol. 2024;166:471-483.
    PubMed     Abstract available


    January 2024
  564. SINGH E, Gurses ME, Costello MC, Lu VM, et al
    Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
    J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-024-04582.
    PubMed     Abstract available


  565. TANAKA T, Tamura R, Takei J, Morimoto Y, et al
    An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
    J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544.
    PubMed     Abstract available


  566. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
    J Neurooncol. 2024 Jan 30. doi: 10.1007/s11060-024-04581.
    PubMed    


  567. DASGUPTA P, Rousseau JF
    Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04574.
    PubMed     Abstract available


  568. PETRONEK MS, Bodeker KL, Lee CY, Teferi N, et al
    Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04571.
    PubMed     Abstract available


  569. VAN OPIJNEN MP, Broekman MLD, Cuppen E, Dubbink HJ, et al
    Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04568.
    PubMed     Abstract available


  570. YEKULA A, Gessler DJ, Ferreira C, Shah R, et al
    GammaTile((R)) (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials.
    J Neurooncol. 2024 Jan 28. doi: 10.1007/s11060-023-04545.
    PubMed     Abstract available


  571. GONZALEZ-APONTE MF, Damato AR, Trebucq LL, Simon T, et al
    Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    J Neurooncol. 2024 Jan 26. doi: 10.1007/s11060-023-04535.
    PubMed     Abstract available


  572. KREATSOULAS D, Damante M, Cua S, Lonser RR, et al
    Adjuvant convection-enhanced delivery for the treatment of brain tumors.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04552.
    PubMed     Abstract available


  573. MULLER SJ, Khadhraoui E, Ganslandt O, Henkes H, et al
    MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-024-04573.
    PubMed     Abstract available


  574. GARCIA MA, Turner A, Brachman DG
    The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04523.
    PubMed     Abstract available


  575. REESE JC, Fadel HA, Pawloski JA, Samir M, et al
    Laser interstitial thermal therapy for deep-seated perivascular brain tumors is not associated with distal ischemia.
    J Neurooncol. 2024 Jan 19. doi: 10.1007/s11060-023-04546.
    PubMed     Abstract available


  576. RYNDA AY, Rostovthev DM, Zabrodskaya YM, Olyushin VE, et al
    Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results.
    J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04559.
    PubMed     Abstract available


  577. ON J, Natsumeda M, Takahashi H, Koyama A, et al
    Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
    J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04555.
    PubMed     Abstract available


  578. ZAPANTA RINONOS S, Li T, Pianka ST, Prins TJ, et al
    dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
    J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04531.
    PubMed     Abstract available


  579. KUAH XYC, Lucas-Herald AK, McCarrison S, Boyle R, et al
    Presentation and outcomes of paediatric craniopharyngioma in the west of Scotland: a 25 year experience.
    J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04490.
    PubMed     Abstract available


  580. DOGAN E, Yildirim Z, Akalin T, Ozgiray E, et al
    Investigating the effects of PTEN mutations on cGAS-STING pathway in glioblastoma tumours.
    J Neurooncol. 2024 Jan 12. doi: 10.1007/s11060-023-04556.
    PubMed     Abstract available


  581. DAGHER R, Gad M, da Silva de Santana P, Sadeghi MA, et al
    Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
    J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-023-04528.
    PubMed     Abstract available


  582. MIYAKOSHI A, Ubukata N, Miyake H, Shoji-Asahina A, et al
    Risk factors for glioblastoma in adults in Japan: an exploratory cohort study based on the Shizuoka Kokuho Database, the Shizuoka study.
    J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-024-04566.
    PubMed     Abstract available


  583. BERGER A, Mullen R, Bernstein K, Mashiach E, et al
    Volumetric growth rate of incidentally found meningiomas on immunotherapy.
    J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04558.
    PubMed     Abstract available


  584. HUDSON K, Mondia MW, Zhang Y, Saha S, et al
    The role of microRNAs in brain metastasis.
    J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04541.
    PubMed     Abstract available


  585. ZHANG Q, Dai Z, Chen Y, Li Q, et al
    Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway.
    J Neurooncol. 2024 Jan 8. doi: 10.1007/s11060-023-04527.
    PubMed     Abstract available


  586. ZEUNER S, Vollmer J, Sigaud R, Oppermann S, et al
    Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
    J Neurooncol. 2024 Jan 7. doi: 10.1007/s11060-023-04526.
    PubMed     Abstract available


  587. YADAV N, Purow BW
    Understanding current experimental models of glioblastoma-brain microenvironment interactions.
    J Neurooncol. 2024 Jan 5. doi: 10.1007/s11060-023-04536.
    PubMed     Abstract available


  588. ZHANG JF, Okai B, Iovoli A, Goulenko V, et al
    Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.
    J Neurooncol. 2024 Jan 4. doi: 10.1007/s11060-023-04524.
    PubMed     Abstract available


  589. KAMBE A, Kitao S, Ochiai R, Hosoya T, et al
    The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
    J Neurooncol. 2024 Jan 2. doi: 10.1007/s11060-023-04550.
    PubMed     Abstract available


  590. HESHAM D, On J, Alshahaby N, Amer N, et al
    Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
    J Neurooncol. 2024;166:27-38.
    PubMed     Abstract available


  591. FADUL CE, Thakur A, Kim J, Kassay-McAllister J, et al
    Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
    J Neurooncol. 2024;166:321-330.
    PubMed     Abstract available


  592. OBRECHT-STURM D, Pfaff E, Mynarek M, Bison B, et al
    Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment.
    J Neurooncol. 2024;166:359-368.
    PubMed     Abstract available


  593. EBADI M, Morse M, Gooley T, Ermoian R, et al
    Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.
    J Neurooncol. 2024;166:351-357.
    PubMed     Abstract available


  594. SHEEHAN JP, Michalopoulos GD, Katsos K, Bydon M, et al
    The NeuroPoint alliance SRS & tumor QOD registries.
    J Neurooncol. 2024;166:257-264.
    PubMed     Abstract available


  595. FENG J, Zhang J, Chen L, Li C, et al
    Treatment outcomes and risk factors of patients with intracranial germ cell tumour with choriocarcinoma element or beta-HCG level higher than 500 IU/L.
    J Neurooncol. 2024;166:331-339.
    PubMed     Abstract available


  596. HONG S, Garces YI, Price KA, Shinya Y, et al
    Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.
    J Neurooncol. 2024;166:369-376.
    PubMed     Abstract available


    December 2023
  597. NORIKANE T, Mitamura K, Yamamoto Y, Manabe Y, et al
    Comparative evaluation of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.
    J Neurooncol. 2023 Dec 31. doi: 10.1007/s11060-023-04534.
    PubMed     Abstract available


  598. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
    J Neurooncol. 2023 Dec 28. doi: 10.1007/s11060-023-04513.
    PubMed     Abstract available


  599. ARORA H, Mammi M, Patel NM, Zyfi D, et al
    Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04549.
    PubMed     Abstract available


  600. YANG ZC, Yin CD, Yeh FC, Xue BW, et al
    Exploring MGMT methylation-driven structural connectivity changes in insular gliomas: a tractography and graph theoretical analysis.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04539.
    PubMed     Abstract available


  601. BENNEBROEK CA, Schouten CR, Montauban-van Swijndregt MC, Saeed P, et al
    Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04516.
    PubMed     Abstract available


  602. REN L, Chen J, Deng J, Qing X, et al
    The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study.
    J Neurooncol. 2023 Dec 26. doi: 10.1007/s11060-023-04511.
    PubMed     Abstract available


  603. CHOU CJ, Yang HC, Chang PY, Chen CJ, et al
    Automated identification and quantification of metastatic brain tumors and perilesional edema based on a deep learning neural network.
    J Neurooncol. 2023 Dec 22. doi: 10.1007/s11060-023-04540.
    PubMed     Abstract available


  604. MIJAJLOVIC V, Miler M, Ilic R, Rasic D, et al
    Oncogene-induced senescence in meningiomas-an immunohistochemical study.
    J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04532.
    PubMed     Abstract available


  605. KINSLOW CJ, Siegelin MD, Iwamoto FM, Gallitto M, et al
    MGMT promoter methylation in 1p19q-intact gliomas.
    J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04515.
    PubMed     Abstract available


  606. LU VM, Khalafallah AM, Jaman E, Gurses ME, et al
    Clinical course of ventriculoperitoneal shunting for hydrocephalus following glioblastoma surgery: a systematic review and meta-analysis.
    J Neurooncol. 2023 Dec 19. doi: 10.1007/s11060-023-04538.
    PubMed     Abstract available


  607. ABETE-FORNARA G, Bintintan Socaciu P, Fanizzi C, Fiore G, et al
    Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study.
    J Neurooncol. 2023 Dec 18. doi: 10.1007/s11060-023-04533.
    PubMed     Abstract available


  608. CHEN Q, Wang K, Ren X, Zhao X, et al
    Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [(11)C]methionine PET.
    J Neurooncol. 2023 Dec 14. doi: 10.1007/s11060-023-04529.
    PubMed     Abstract available


  609. CHANG CT, Chen HH, Chuang CC, Chang SH, et al
    Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.
    J Neurooncol. 2023 Dec 8. doi: 10.1007/s11060-023-04503.
    PubMed     Abstract available


  610. CHEN KT, Huang CY, Pai PC, Yang WC, et al
    Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
    J Neurooncol. 2023 Dec 7. doi: 10.1007/s11060-023-04517.
    PubMed     Abstract available


  611. MIAO Q, Zheng X, Li L, Zheng X, et al
    Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    J Neurooncol. 2023;165:517-525.
    PubMed     Abstract available


  612. WILLEMS YCP, Vaassen F, Zegers CML, Postma AA, et al
    Anatomical changes in resection cavity during brain radiotherapy.
    J Neurooncol. 2023;165:479-486.
    PubMed     Abstract available


  613. RAMMELOO E, Schouten JW, Krikour K, Bos EM, et al
    Preoperative assessment of eloquence in neurosurgery: a systematic review.
    J Neurooncol. 2023;165:413-430.
    PubMed     Abstract available


  614. SHEN CI, Chiang CL, Huang HC, Tseng YH, et al
    Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study.
    J Neurooncol. 2023;165:459-465.
    PubMed     Abstract available


  615. WIJAYA JH, Patel UD, Quintero-Consuegra MD, Aguilera-Pena MP, et al
    Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis.
    J Neurooncol. 2023;165:431-438.
    PubMed     Abstract available


  616. LYNES J, Khan I, Aguilera C, Rubino S, et al
    Development of a "Geo-Tagged" tumor sample registry: intra-operative linkage of sample location to imaging.
    J Neurooncol. 2023;165:449-458.
    PubMed     Abstract available


  617. SELT F, El Damaty A, Schuhmann MU, Sigaud R, et al
    Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.
    J Neurooncol. 2023;165:467-478.
    PubMed     Abstract available


    November 2023
  618. SHEEHAN J, Mantziaris G, Dumont C, Pikis S, et al
    Incidental meningiomas: a current and increasingly common challenge.
    J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04525.
    PubMed    


  619. BAUMGARTEN P, Prange G, Kamp MA, Monden D, et al
    Treatment of very elderly glioblastoma patients >/= 75 years of age: whom to treat.
    J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04518.
    PubMed     Abstract available


  620. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
    Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
    J Neurooncol. 2023 Nov 29. doi: 10.1007/s11060-023-04491.
    PubMed     Abstract available


  621. KLEINBERG L, Ye X, Supko J, Stevens GHJ, et al
    A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
    J Neurooncol. 2023 Nov 28. doi: 10.1007/s11060-023-04514.
    PubMed     Abstract available


  622. YAVUZ BB, Kilinc F, Kanyilmaz G, Aktan M, et al
    Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients.
    J Neurooncol. 2023 Nov 27. doi: 10.1007/s11060-023-04521.
    PubMed     Abstract available


  623. CHIANG CL, Yang HC, Liao YT, Luo YH, et al
    Treatment and survival of patients with small cell lung cancer and brain metastasis.
    J Neurooncol. 2023 Nov 20. doi: 10.1007/s11060-023-04512.
    PubMed     Abstract available


  624. QIU X, Gao J, Hu J, Yang J, et al
    Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center.
    J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04401.
    PubMed     Abstract available


  625. QIN N, Paisana E, Picard D, Leprivier G, et al
    The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
    J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04508.
    PubMed     Abstract available


  626. VOGLIS S, Padevit L, van Niftrik CHB, Kalin V, et al
    Safety of microneurosurgical interventions for superficial and deep-seated brain metastases: single-center cohort study of 637 consecutive cases.
    J Neurooncol. 2023 Nov 10. doi: 10.1007/s11060-023-04478.
    PubMed     Abstract available


  627. KHAN AB, Dang HQ, Gopakumar S, Lazaro T, et al
    Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.
    J Neurooncol. 2023 Nov 9. doi: 10.1007/s11060-023-04475.
    PubMed     Abstract available


  628. KIM N, Lee J, Nam DH, Lee JI, et al
    Correction to: Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
    J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04498.
    PubMed    


  629. NASLUND O, Strand PS, Solheim O, Al Masri M, et al
    Incidence, management, and outcome of incidental meningioma: what has happened in 10 years?
    J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04482.
    PubMed     Abstract available


  630. YAMAMOTO S, Okita Y, Arita H, Sanada T, et al
    Qualitative MR features to identify non-enhancing tumors within glioblastoma's T2-FLAIR hyperintense lesions.
    J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04454.
    PubMed     Abstract available


  631. LIN HT, Lin CM, Wu YY, Chang WH, et al
    Predictors for delayed awakening in adult glioma patients receiving awake craniotomy under monitored anesthesia care.
    J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04494.
    PubMed     Abstract available


  632. CHEN YH, Moore D, Lee CC, Su YH, et al
    Focused ultrasound for brain metastases: an update on global clinical trials.
    J Neurooncol. 2023 Nov 1. doi: 10.1007/s11060-023-04492.
    PubMed     Abstract available


  633. HONG Y, Miao Q, Zheng X, Xu Y, et al
    Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
    J Neurooncol. 2023;165:301-312.
    PubMed     Abstract available


  634. PRICE M, Neff C, Kruchko C, Barnholtz-Sloan JS, et al
    Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT.
    J Neurooncol. 2023;165:279-290.
    PubMed     Abstract available


  635. KO MK, Kwak YK, Choi BO, Jeun SS, et al
    Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?
    J Neurooncol. 2023;165:321-328.
    PubMed     Abstract available


  636. ZAMARUD A, Marianayagam NJ, Park DJ, Yener U, et al
    The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    J Neurooncol. 2023;165:373-379.
    PubMed     Abstract available


    October 2023
  637. KRASSNIG S, Leber SL, Orthmann A, Golob-Schwarzl N, et al
    Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
    J Neurooncol. 2023 Oct 31. doi: 10.1007/s11060-023-04451.
    PubMed     Abstract available


  638. LEHRER EJ, Khosla AA, Ozair A, Gurewitz J, et al
    Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04413.
    PubMed     Abstract available


  639. MOHAMMAD AH, Jatana S, Ruiz-Barerra MA, Khalaf R, et al
    Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04485.
    PubMed     Abstract available


  640. MA S, Lee H, Jo WY, Byun YH, et al
    The Warburg effect in patients with brain tumors: a comprehensive analysis of clinical significance.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04486.
    PubMed     Abstract available


  641. CROMPTON D, Koffler D, Fekrmandi F, Lehrer EJ, et al
    Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04466.
    PubMed     Abstract available


  642. GROB ST, Miller KR, Sanford B, Donson AM, et al
    Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors.
    J Neurooncol. 2023 Oct 25. doi: 10.1007/s11060-023-04472.
    PubMed     Abstract available


  643. ELLIS EM, Drumm MR, Rai SM, Huang J, et al
    Long-term antiseizure medication use in patients after meningioma resection: identifying predictors for successful weaning and failures.
    J Neurooncol. 2023 Oct 24. doi: 10.1007/s11060-023-04481.
    PubMed     Abstract available


  644. STROWD R, Ellingson B, Raymond C, Yao J, et al
    Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
    J Neurooncol. 2023 Oct 21. doi: 10.1007/s11060-023-04456.
    PubMed     Abstract available


  645. KIM N, Lee J, Nam DH, Lee JI, et al
    Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
    J Neurooncol. 2023 Oct 20. doi: 10.1007/s11060-023-04465.
    PubMed     Abstract available


  646. YU Y, Chen H, Tian Z, Zhang Q, et al
    Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.
    J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04459.
    PubMed     Abstract available


  647. NAKAJIMA R, Kinoshita M, Okita H, Nakada M, et al
    Glioblastomas at the white matter of temporo-parietal junction cause a poor postoperative independence level.
    J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04479.
    PubMed     Abstract available


  648. HOU C, Shi S, Gao M, Ji J, et al
    Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy.
    J Neurooncol. 2023 Oct 11. doi: 10.1007/s11060-023-04449.
    PubMed     Abstract available


  649. DEJONCKHEERE CS, Layer JP, Hamed M, Layer K, et al
    Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04464.
    PubMed     Abstract available


  650. BORST GR, Post R
    Letter to the editor: the impact of systemic treatment on brain metastases should be considered in clinical outcome analysis.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04457.
    PubMed    


  651. PANDYA SHESH B, Walter V, Palsa K, Slagle-Webb B, et al
    Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04415.
    PubMed     Abstract available


  652. ERNSTER AE, Body A, Deleyrolle P, St Clair J, et al
    Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors.
    J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04469.
    PubMed     Abstract available


  653. KOTCH C, Si SJ, Desai K, Caminada P, et al
    The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
    J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04468.
    PubMed     Abstract available


  654. DADEY DYA, Medress ZA, Sharma M, Ugiliweneza B, et al
    Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018.
    J Neurooncol. 2023 Oct 4. doi: 10.1007/s11060-023-04460.
    PubMed     Abstract available


  655. COVELL MM, Warrier A, Rumalla KC, Dehney CM, et al
    RAI-measured frailty predicts non-home discharge following metastatic brain tumor resection: national inpatient sample analysis of 20,185 patients.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04461.
    PubMed     Abstract available


  656. WELLER J, Zeyen T, Schafer N, Schaub C, et al
    The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04470.
    PubMed     Abstract available


  657. VOLLMER J, Ecker J, Hielscher T, Valinciute G, et al
    Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04445.
    PubMed     Abstract available


  658. QUE T, Huang G, Tan JE, Zhang P, et al
    Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma.
    J Neurooncol. 2023 Oct 2. doi: 10.1007/s11060-023-04399.
    PubMed     Abstract available


  659. STOCKDILL ML, Mendoza T, Armstrong TS, Miaskowski C, et al
    Identification of health-related quality of life profiles among long-term survivors of primary central nervous system tumors.
    J Neurooncol. 2023;165:181-190.
    PubMed     Abstract available


  660. BAI K, Chen X, Qi X, Zhang Y, et al
    Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    J Neurooncol. 2023;165:149-160.
    PubMed     Abstract available


  661. ONISHI S, Yamasaki F, Amatya VJ, Takayasu T, et al
    Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
    J Neurooncol. 2023;165:171-179.
    PubMed     Abstract available


  662. GUTIERREZ-VALENCIA E, Sanchez I, Valles A, Diaz O, et al
    Pachymeningeal disease: a systematic review and metanalysis.
    J Neurooncol. 2023;165:29-39.
    PubMed     Abstract available


    September 2023
  663. VAN T HEK R, Ortiz-Herrera JL, Salazar-Pigeon A, Ramirez-Loera C, et al
    Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis.
    J Neurooncol. 2023 Sep 29. doi: 10.1007/s11060-023-04448.
    PubMed     Abstract available


  664. KARABACAK M, Jagtiani P, Carrasquilla A, Shrivastava RK, et al
    Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models.
    J Neurooncol. 2023 Sep 28. doi: 10.1007/s11060-023-04463.
    PubMed     Abstract available


  665. VAN DER MEER PB, Dirven L, Fiocco M, Vos MJ, et al
    Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study.
    J Neurooncol. 2023 Sep 27. doi: 10.1007/s11060-023-04450.
    PubMed     Abstract available


  666. LI L, Shao MY, Zou SC, Xiao ZF, et al
    Correction to: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44.
    J Neurooncol. 2023 Sep 22. doi: 10.1007/s11060-023-04429.
    PubMed    


  667. MARWAH R, Xing D, Squire T, Soon YY, et al
    Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
    J Neurooncol. 2023 Sep 21. doi: 10.1007/s11060-023-04441.
    PubMed     Abstract available


  668. SHEEHAN JP, Trifiletti DM
    Comments: neurosurgery and radiation oncology advances have improved visual outcomes for skull base meningioma patients.
    J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04400.
    PubMed    


  669. KUAN AS, Chiang CL, Wu HM, Yang HC, et al
    Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04452.
    PubMed     Abstract available


  670. FURUTA T, Negoto T, Miyoshi H, Moritsubo M, et al
    Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04447.
    PubMed     Abstract available


  671. IGLSEDER S, Iglseder A, Beliveau V, Heugenhauser J, et al
    Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04414.
    PubMed     Abstract available


  672. KATLOWITZ KA, Athukuri P, Sharma H, Dang H, et al
    Seizure outcomes after resection of primary brain tumors in pediatric patients: a systematic review and meta-analysis.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04446.
    PubMed     Abstract available


  673. JABEHDAR MARALANI P, Stewart J, Hiremath S, Lawrence L, et al
    Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04440.
    PubMed     Abstract available


  674. DIMOV D, Brainman D, Berger B, Coras R, et al
    The role of cytoreductive surgery in multifocal/multicentric glioblastomas.
    J Neurooncol. 2023 Sep 12. doi: 10.1007/s11060-023-04410.
    PubMed     Abstract available


  675. NINATTI G, Pini C, Bono BC, Gelardi F, et al
    The prognostic power of [(11)C]methionine PET in IDH-wildtype diffuse gliomas with lower-grade histological features: venturing beyond WHO classification.
    J Neurooncol. 2023 Sep 11. doi: 10.1007/s11060-023-04438.
    PubMed     Abstract available


  676. ALZATE JD, Mullen R, Mashiach E, Bernstein K, et al
    EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.
    J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04442.
    PubMed     Abstract available


  677. SOHN B, Park K, Ahn SS, Park YW, et al
    Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
    J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04435.
    PubMed     Abstract available


  678. HOU Z, Hu J, Liu X, Yan Z, et al
    Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04420.
    PubMed     Abstract available


  679. WU YY, Chen KT, Chu YC, Yeh CC, et al
    Neuropsychological impairment in primary malignant brain tumor patients with awake craniotomy: a hospital-based registration study.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04431.
    PubMed     Abstract available


  680. MURTHA AN, Zaki PG, Shepard MJ
    Letter to the editor: outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04434.
    PubMed    


  681. LUCKETT PH, Olufawo M, Lamichhane B, Park KY, et al
    Predicting survival in glioblastoma with multimodal neuroimaging and machine learning.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04439.
    PubMed     Abstract available


  682. HUNG JS, Su YH, Chen CJ, Chiang CL, et al
    Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.
    J Neurooncol. 2023 Sep 1. doi: 10.1007/s11060-023-04425.
    PubMed     Abstract available


  683. CIFARELLI CP, Vargo JA, Sener U, Cifarelli DT, et al
    Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.
    J Neurooncol. 2023;164:423-430.
    PubMed     Abstract available


  684. MINNITI G, Paolini S, Antonelli M, Gianno F, et al
    Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
    J Neurooncol. 2023;164:331-339.
    PubMed     Abstract available


  685. HOU L, Chen X, Qiu G, Qi X, et al
    Cerebrospinal fluid exosomal protein alterations via proteomic analysis of NSCLC with leptomeningeal carcinomatosis.
    J Neurooncol. 2023;164:367-376.
    PubMed     Abstract available


  686. FIGUEREDO LF, Shelton WJ, Tagle-Vega U, Sanchez E, et al
    The state of art of awake craniotomy in Latin American countries: a scoping review.
    J Neurooncol. 2023;164:287-298.
    PubMed     Abstract available


  687. ID SAID B, Soliman H, Moravan V, Myrehaug S, et al
    Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
    J Neurooncol. 2023;164:437-445.
    PubMed     Abstract available


  688. ZENG C, Yang Q, Li Z, Wei Z, et al
    Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study.
    J Neurooncol. 2023;164:643-653.
    PubMed     Abstract available


  689. ZEYEN T, Paech D, Weller J, Schafer N, et al
    Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
    J Neurooncol. 2023;164:607-616.
    PubMed     Abstract available


    August 2023
  690. PERTZ M, Schlomer S, Seidel C, Hentschel B, et al
    Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.
    J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04419.
    PubMed     Abstract available


  691. JIA W, Zhai X, Jing X, Bao Q, et al
    Prognostic value of cranial radiotherapy and optimal timing stratified by lung-molGPA for NSCLC patients with brain metastases.
    J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04426.
    PubMed     Abstract available


  692. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
    Publisher Correction to: Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
    J Neurooncol. 2023 Aug 29. doi: 10.1007/s11060-023-04424.
    PubMed    


  693. QURESHI HM, Tabor JK, Pickens K, Lei H, et al
    Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.
    J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04416.
    PubMed     Abstract available


  694. DE PIETRO R, Zaccaro L, Marampon F, Tini P, et al
    The evolving role of reirradiation in the management of recurrent brain tumors.
    J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04407.
    PubMed     Abstract available


  695. LEHRER EJ, Trifiletti DM, Sheehan JP
    Stereotactic radiosurgery in patients with extensive brain metastases - supporting evidence and knowledge gaps.
    J Neurooncol. 2023 Aug 21. doi: 10.1007/s11060-023-04422.
    PubMed    


  696. EBIKO Y, Tamura K, Hara S, Inaji M, et al
    T2-FLAIR mismatch sign correlates with (11)C-methionine uptake in lower-grade diffuse gliomas.
    J Neurooncol. 2023 Aug 17. doi: 10.1007/s11060-023-04417.
    PubMed     Abstract available


  697. GURRIERI L, Mercatali L, Ibrahim T, Fausti V, et al
    Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.
    J Neurooncol. 2023 Aug 16. doi: 10.1007/s11060-023-04357.
    PubMed     Abstract available


  698. LAWSON MCLEAN A
    Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
    J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04408.
    PubMed    


  699. MIER-GARCIA JF, Ospina-Santa S, Orozco-Mera J, Ma R, et al
    Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.
    J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04409.
    PubMed     Abstract available


  700. JABLONSKA PA, Muniz T, Ribeiro M, Liu ZA, et al
    Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
    J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04404.
    PubMed     Abstract available


  701. OTANI R, Ikegami M, Yamada R, Yajima H, et al
    PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
    J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04411.
    PubMed     Abstract available


  702. HOLDAWAY M, Ablyazova F, Huda S, D'Amico RS, et al
    First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.
    J Neurooncol. 2023 Aug 7. doi: 10.1007/s11060-023-04412.
    PubMed     Abstract available


  703. LANG A, Jeron RL, Lontzek B, Kiesel B, et al
    Mapping high-grade glioma immune infiltration to 5-ALA fluorescence levels: TCGA data computation, classical histology, and digital image analysis.
    J Neurooncol. 2023 Aug 6. doi: 10.1007/s11060-023-04406.
    PubMed     Abstract available


  704. NEUMANN B, Onken J, Konig N, Stetefeld H, et al
    Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
    J Neurooncol. 2023 Aug 2. doi: 10.1007/s11060-023-04403.
    PubMed     Abstract available


  705. AKINDURO OO, Ghaith AK, El-Hajj VG, Ghanem M, et al
    Effect of race, sex, and socioeconomic factors on overall survival following the resection of intramedullary spinal cord tumors.
    J Neurooncol. 2023;164:75-85.
    PubMed     Abstract available


  706. NETH BJ, Webb MJ, White J, Uhm JH, et al
    Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
    J Neurooncol. 2023;164:239-247.
    PubMed     Abstract available


    July 2023
  707. NODA R, Kawashima M, Segawa M, Tsunoda S, et al
    Fractionated versus staged gamma knife radiosurgery for mid-to-large brain metastases: a propensity score-matched analysis.
    J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04374.
    PubMed     Abstract available


  708. HU T, Xuan R, Han E, Cai L, et al
    SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling.
    J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04394.
    PubMed     Abstract available


  709. MANTICA M, Drappatz J, Lieberman F, Hadjipanayis CG, et al
    Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
    J Neurooncol. 2023 Jul 29. doi: 10.1007/s11060-023-04398.
    PubMed     Abstract available


  710. VIOZZI I, Overduin CG, Rijpma A, Rovers MM, et al
    MR-guided LITT therapy in patients with primary irresectable glioblastoma: a prospective, controlled pilot study.
    J Neurooncol. 2023 Jul 28. doi: 10.1007/s11060-023-04371.
    PubMed     Abstract available


  711. BALLO MT, Conlon P, Lavy-Shahaf G, Kinzel A, et al
    Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
    J Neurooncol. 2023 Jul 26. doi: 10.1007/s11060-023-04348.
    PubMed     Abstract available


  712. RAVIN R, Suarez-Meade P, Busse B, Blank PS, et al
    Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.
    J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04349.
    PubMed     Abstract available


  713. KHATRI VM, Mills MN, Oliver DE, Yu HM, et al
    Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
    J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04402.
    PubMed     Abstract available


  714. SPILLE DC, Thomas C, Wagner A, Grauer OM, et al
    Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
    J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04379.
    PubMed     Abstract available


  715. LAYER JP, Hamed M, Potthoff AL, Dejonckheere CS, et al
    Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
    J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04380.
    PubMed     Abstract available


  716. BUYUKTEPE M, Kaplan I, Bayatli E, Dogan H, et al
    Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04397.
    PubMed     Abstract available


  717. ZHANG YT, Wang Y, Zhong XD, Chang J, et al
    Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04388.
    PubMed     Abstract available


  718. TAORI S, Wei Z, Deng H, Hadjipanayis CG, et al
    Stereotactic radiosurgery for patients with brain metastases from gastroesophageal cancers.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04392.
    PubMed     Abstract available


  719. YANG X, Ji C, Qi Y, Huang J, et al
    Signal-transducing adaptor protein 1 (STAP1) in microglia promotes the malignant progression of glioma.
    J Neurooncol. 2023 Jul 18. doi: 10.1007/s11060-023-04390.
    PubMed     Abstract available


  720. CHOJAK R, Fares J, Petrosyan E, Lesniak MS, et al
    Cellular senescence in glioma.
    J Neurooncol. 2023 Jul 17. doi: 10.1007/s11060-023-04387.
    PubMed     Abstract available


  721. MALLICK S, Gupta S, Amariyil A, Kunhiparambath H, et al
    Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
    J Neurooncol. 2023 Jul 15. doi: 10.1007/s11060-023-04391.
    PubMed     Abstract available


  722. ONYIAH C, Shepard MJ
    Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04376.
    PubMed    


  723. MATSUI JK, Allen PK, Perlow HK, Johnson JM, et al
    Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04386.
    PubMed     Abstract available


  724. OTANI R, Sadato D, Yamada R, Yajima H, et al
    CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04381.
    PubMed     Abstract available


  725. LEI H, Tabor JK, O'Brien J, Qin R, et al
    Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04393.
    PubMed     Abstract available


  726. INDHARTY RS, Japardi I, Irina RS, Tandean S, et al
    Comparison of direct cortical stimulation and transcranial magnetic stimulation in brain tumor surgery: systematic review and meta analyses.
    J Neurooncol. 2023 Jul 12. doi: 10.1007/s11060-023-04378.
    PubMed     Abstract available


  727. YADAV N, Babu D, Madigubba S, Panigrahi M, et al
    Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway.
    J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04383.
    PubMed     Abstract available


  728. MISHRA A, Koffler D, Calugaru E, Rowe N, et al
    Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases.
    J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04365.
    PubMed     Abstract available


  729. TANRIKULU B, Yasar AH, Canpolat C, Corapcioglu F, et al
    Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas.
    J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04347.
    PubMed     Abstract available


  730. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
    Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
    J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04344.
    PubMed     Abstract available


  731. LUO M, Tang R, Wang H
    Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    J Neurooncol. 2023;163:663-674.
    PubMed     Abstract available


  732. LESKINEN S, Shah HA, Yaffe B, Schneider SJ, et al
    Hippocampal avoidance in whole brain radiotherapy and prophylactic cranial irradiation: a systematic review and meta-analysis.
    J Neurooncol. 2023;163:515-527.
    PubMed     Abstract available


    June 2023
  733. JONNAKUTI VS, Ji P, Gao Y, Lin A, et al
    NUDT21 alters glioma migration through differential alternative polyadenylation of LAMC1.
    J Neurooncol. 2023 Jun 30. doi: 10.1007/s11060-023-04370.
    PubMed     Abstract available


  734. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
    J Neurooncol. 2023 Jun 29. doi: 10.1007/s11060-023-04367.
    PubMed     Abstract available


  735. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
    Correction to: Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
    J Neurooncol. 2023 Jun 28. doi: 10.1007/s11060-023-04364.
    PubMed    


  736. ADILE AA, Bakhshinyan D, Suk Y, Uehling D, et al
    An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
    J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04372.
    PubMed     Abstract available


  737. HOLDAWAY M, Starner J, Patel RR, Salama J, et al
    Improvement in visual outcomes of patients with base of skull meningioma as a result of evolution in the treatment techniques in the last three decades: a systematic review.
    J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04366.
    PubMed     Abstract available


  738. CHEN J, Li T, Zhou N, He Y, et al
    Engineered Salmonella inhibits GPX4 expression and induces ferroptosis to suppress glioma growth in vitro and in vivo.
    J Neurooncol. 2023 Jun 23. doi: 10.1007/s11060-023-04369.
    PubMed     Abstract available


  739. TOM MC, DiFilippo FP, Jones SE, Suh JH, et al
    (18)F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study.
    J Neurooncol. 2023 Jun 21. doi: 10.1007/s11060-023-04377.
    PubMed     Abstract available


  740. MASSIMINO M, Vennarini S, Buttarelli FR, Antonelli M, et al
    Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
    J Neurooncol. 2023 Jun 16. doi: 10.1007/s11060-023-04361.
    PubMed     Abstract available


  741. KHAN AB, Patel R, McDonald MF, Goethe E, et al
    Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers.
    J Neurooncol. 2023 Jun 15. doi: 10.1007/s11060-023-04359.
    PubMed     Abstract available


  742. JOST J, Muther M, Brandt R, Altuner U, et al
    Conceptual development of an intensive exercise program for glioma patients (ActiNO): summary of clinical experience.
    J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04354.
    PubMed     Abstract available


  743. MERENZON MA, Levy AS, Bhatia S, Rivera C, et al
    Towards the definition of progressive disease in brain metastasis treated with laser ablation: an evidence-based study.
    J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04360.
    PubMed     Abstract available


  744. CHO NS, Sanvito F, Thakuria S, Wang C, et al
    Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas.
    J Neurooncol. 2023 Jun 9. doi: 10.1007/s11060-023-04363.
    PubMed     Abstract available


  745. WELLER J, Katzendobler S, Niedermeyer S, Harter PN, et al
    Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
    J Neurooncol. 2023 Jun 8. doi: 10.1007/s11060-023-04362.
    PubMed     Abstract available


  746. NAGAI N, Koide Y, Shindo Y, Hashimoto S, et al
    Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases.
    J Neurooncol. 2023 Jun 7. doi: 10.1007/s11060-023-04358.
    PubMed     Abstract available


  747. TOKLU S, Kemerdere R, Kacira T, Gurses MS, et al
    Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients.
    J Neurooncol. 2023 Jun 6. doi: 10.1007/s11060-023-04329.
    PubMed     Abstract available


  748. MA J, Li D, Hong Y, Zhang Y, et al
    Different clinical and cytogenetic features of primary skull base meningiomas and non-skull base meningiomas.
    J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04351.
    PubMed     Abstract available


  749. VAN SCHIE P, Rijksen BLT, Bot M, Wiersma T, et al
    Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series.
    J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04343.
    PubMed     Abstract available


  750. CACCESE M, Desideri I, Padovan M, Bruno F, et al
    Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
    J Neurooncol. 2023 Jun 1. doi: 10.1007/s11060-023-04356.
    PubMed     Abstract available


  751. BISWAS A, Salvucci M, Connor K, Dussmann H, et al
    Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
    J Neurooncol. 2023;163:327-338.
    PubMed     Abstract available


    May 2023
  752. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
    Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
    J Neurooncol. 2023 May 31. doi: 10.1007/s11060-023-04340.
    PubMed     Abstract available


  753. BANDER ED, Kelly A, Ma X, Christos PJ, et al
    Safety and efficacy of Cesium-131 brachytherapy for brain tumors.
    J Neurooncol. 2023 May 30. doi: 10.1007/s11060-023-04352.
    PubMed     Abstract available


  754. MCLAUGHLIN LA, Yildirim O, Rosenblum MK, Imber BS, et al
    Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
    J Neurooncol. 2023 May 29. doi: 10.1007/s11060-023-04355.
    PubMed     Abstract available


  755. SHEEHAN J, Cifarelli CP, Fadul C
    Contemporary care for brain metastasis patients: multidisciplinary approaches and the role of prospective national registries.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04350.
    PubMed    


  756. BUSCH N, Wegner RE, Shepard MJ
    Letter to the editor: neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04345.
    PubMed    


  757. TINI P, Yavoroska M, Mazzei MA, Miracco C, et al
    Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04342.
    PubMed     Abstract available


  758. JURATLI TA, Jungk C, Miller JJ
    Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.
    J Neurooncol. 2023 May 22. doi: 10.1007/s11060-023-04317.
    PubMed    


  759. CROOMS RC, Taylor JW, Jette N, Morgenstern R, et al
    Palliative care referral across the disease trajectory in high-grade glioma.
    J Neurooncol. 2023 May 20. doi: 10.1007/s11060-023-04338.
    PubMed     Abstract available


  760. FENG X, Zhu F, Dai L, Liu X, et al
    Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.
    J Neurooncol. 2023 May 17. doi: 10.1007/s11060-023-04339.
    PubMed     Abstract available


  761. KNIGHT A, Horsley P, Yuile A, Yim J, et al
    Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.
    J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04332.
    PubMed     Abstract available


  762. VALINCIUTE G, Ecker J, Selt F, Hielscher T, et al
    Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
    J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04319.
    PubMed     Abstract available


  763. BONOSI L, Marino S, Benigno UE, Musso S, et al
    Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
    J Neurooncol. 2023 May 14. doi: 10.1007/s11060-023-04333.
    PubMed     Abstract available


  764. ZILIOLI A, Misirocchi F, Mutti C, Pancaldi B, et al
    Volumetric hippocampal changes in glioblastoma: a biomarker for neuroplasticity?
    J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04315.
    PubMed     Abstract available


  765. MA Y, Shi F, Sun T, Chen H, et al
    Histopathological auxiliary system for brain tumour (HAS-Bt) based on weakly supervised learning using a WHO CNS5-style pipeline.
    J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04306.
    PubMed     Abstract available


  766. MERLIN MS, Schmitt E, Mezloy-Destracque M, Dufour C, et al
    Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.
    J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04328.
    PubMed     Abstract available


  767. PADILLA CS, Ho VKY, Mooijenkind TWAN, Louwman MWJ, et al
    Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).
    J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04335.
    PubMed     Abstract available


  768. ZABEK T, Szmatola T, Adamczyk-Grochala J, Lewinska A, et al
    Knockout of TRDMT1 methyltransferase affects DNA methylome in glioblastoma cells.
    J Neurooncol. 2023 May 11. doi: 10.1007/s11060-023-04304.
    PubMed     Abstract available


  769. KALYVAS A, Gutierrez-Valencia E, Lau R, Ye XY, et al
    Anatomical and surgical characteristics correlate with pachymeningeal failure in patients with brain metastases after neurosurgical resection and adjuvant stereotactic radiosurgery.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04325.
    PubMed     Abstract available


  770. REGLI LKP, Huijs SMH, Pasmans RCOS, Leue C, et al
    Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04326.
    PubMed     Abstract available


  771. SAUNDERS JT, Kumar S, Benavides-Serrato A, Holmes B, et al
    Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04331.
    PubMed     Abstract available


  772. LAZZARINI E, Silvestris DA, Benvenuto G, Osti D, et al
    Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
    J Neurooncol. 2023 May 4. doi: 10.1007/s11060-023-04287.
    PubMed     Abstract available


  773. ZUO P, Li Y, Wang T, Lin X, et al
    A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
    J Neurooncol. 2023 May 3. doi: 10.1007/s11060-023-04323.
    PubMed     Abstract available


  774. FISHMAN H, Monin R, Dor-On E, Kinzel A, et al
    Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04308.
    PubMed     Abstract available


  775. TRAVERS SS, Fisher CM, Kabos P, Cittelly DM, et al
    Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04314.
    PubMed     Abstract available


  776. DE GODOY LL, Chawla S, Brem S, Wang S, et al
    Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04324.
    PubMed     Abstract available


  777. YE L, Wu BS, Xu ZA, Ji XF, et al
    Evidence for an intra-tumoral microbiome in pituitary neuroendocrine tumors with different clinical phenotypes.
    J Neurooncol. 2023;163:133-142.
    PubMed     Abstract available


  778. DEWAN MC, Isaacs AM, Cools MJ, Yengo-Kahn A, et al
    Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network.
    J Neurooncol. 2023;163:123-132.
    PubMed     Abstract available


  779. LI Q, Ma Y, Lin Z, Ma J, et al
    A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    J Neurooncol. 2023;163:39-46.
    PubMed     Abstract available


    April 2023
  780. AMELOT A, Terrier LM, Cognacq G, Jecko V, et al
    Correction to: Natural history of spinal cord metastasis from brain glioblastomas.
    J Neurooncol. 2023 Apr 26. doi: 10.1007/s11060-023-04320.
    PubMed    


  781. SENGUPTA S
    Integrative neuro-oncology for brain tumor patients.
    J Neurooncol. 2023 Apr 25. doi: 10.1007/s11060-023-04309.
    PubMed    


  782. CHANG WH, Wei KC, Chen PY, Chen YC, et al
    The impact of patient factors and tumor characteristics on language neuroplasticity in left hemispheric diffuse gliomas prior to surgical resection.
    J Neurooncol. 2023 Apr 24. doi: 10.1007/s11060-023-04311.
    PubMed     Abstract available


  783. TRACZ JA, Donnelly BM, Ngu S, Vojnic M, et al
    The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
    J Neurooncol. 2023 Apr 22. doi: 10.1007/s11060-023-04312.
    PubMed     Abstract available


  784. SYED HR, Kilburn L, Fonseca A, Nazarian J, et al
    First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication.
    J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04269.
    PubMed    


  785. DEMETZ M, Krigers A, Moser P, Kerschbaumer J, et al
    Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival.
    J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04301.
    PubMed     Abstract available


  786. ALTIERI R, Certo F, Pacella D, Cammarata G, et al
    Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection.
    J Neurooncol. 2023 Apr 11. doi: 10.1007/s11060-023-04305.
    PubMed     Abstract available


  787. VOON NS, Manan HA, Yahya N
    Remote assessment of cognition and quality of life following radiotherapy for glioma: deep-learning-based predictive models and MRI correlates.
    J Neurooncol. 2023 Apr 4:1-9. doi: 10.1007/s11060-023-04303.
    PubMed     Abstract available


  788. DINCER A, Morales-Valero SF, Robert SM, Tabor JK, et al
    Surgical strategies for intracranial meningioma in the molecular era.
    J Neurooncol. 2023 Apr 3. doi: 10.1007/s11060-023-04272.
    PubMed     Abstract available


  789. YAMASHITA S, Takeshima H, Hata N, Uchida H, et al
    Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.
    J Neurooncol. 2023;162:425-433.
    PubMed     Abstract available


  790. FOO JC, Yaman Bajin I, Marushchak O, McKeown T, et al
    Time to dismiss boost? Outcomes of children with localized and metastatic germinoma.
    J Neurooncol. 2023;162:443-448.
    PubMed     Abstract available


  791. ROEHRIG A, Indelicato DJ, Paulino AC, Ermoian R, et al
    Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
    J Neurooncol. 2023;162:353-362.
    PubMed     Abstract available


  792. KEARNS K, Shepard MJ, Sheehan JP
    Social media and the Journal of Neuro-Oncology.
    J Neurooncol. 2023;162:453-454.
    PubMed    


    March 2023
  793. AYMERIC A, Louis-Marie T, Gabrielle C, Vincent J, et al
    Natural history of spinal cord metastasis from brain glioblastomas.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04298.
    PubMed     Abstract available


  794. QUAN G, Wang T, Ren JL, Xue X, et al
    Prognostic and predictive impact of abnormal signal volume evolution early after chemoradiotherapy in glioblastoma.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04299.
    PubMed     Abstract available


  795. CHAMPEAUX-DEPOND C, Jecko V, Weller J, Constantinou P, et al
    Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04295.
    PubMed     Abstract available


  796. OZKARA BB, Federau C, Dagher SA, Pattnaik D, et al
    Correlating volumetric and linear measurements of brain metastases on MRI scans using intelligent automation software: a preliminary study.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04297.
    PubMed     Abstract available


  797. ZHA B, Yang J, Dang Q, Li P, et al
    A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04292.
    PubMed     Abstract available


  798. POPPE JP, Schwartz C
    In reply to the letter to the editor by Busch et al. regarding "Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study".
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04302.
    PubMed    


  799. KIMURA K, Deguchi S, Mitsuya K, Mamesaya N, et al
    Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.
    J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04300.
    PubMed     Abstract available


  800. WAMELINK IJHG, Hempel HL, van de Giessen E, Vries MHM, et al
    The patients' experience of neuroimaging of primary brain tumors: a cross-sectional survey study.
    J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04290.
    PubMed     Abstract available


  801. IUS T, Sabatino G, Panciani PP, Fontanella MM, et al
    Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch(R)): a systematic review.
    J Neurooncol. 2023 Mar 24. doi: 10.1007/s11060-023-04274.
    PubMed     Abstract available


  802. PARSONS MW, Sabsevitz DS
    Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.
    J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04289.
    PubMed     Abstract available


  803. LIANG L, Wen L, Qin S, He Z, et al
    Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM-IPTW cohort study.
    J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04293.
    PubMed     Abstract available


  804. SHAH DS, Reddy RV, Dogruel Y, Asfour MZ, et al
    Calcified spinal meningiomas: a systematic review of clinical characteristics, treatment strategies, and outcomes.
    J Neurooncol. 2023 Mar 17. doi: 10.1007/s11060-023-04291.
    PubMed     Abstract available


  805. QUACH S, Schwartz C, Aumiller M, Foglar M, et al
    Interstitial photodynamic therapy for newly diagnosed glioblastoma.
    J Neurooncol. 2023 Mar 16. doi: 10.1007/s11060-023-04284.
    PubMed     Abstract available


  806. BLEEKER L, Kouwenhoven MCM, de Heer I, Lissenberg-Witte BI, et al
    Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol.
    J Neurooncol. 2023 Mar 15. doi: 10.1007/s11060-023-04285.
    PubMed     Abstract available


  807. YAN M, Lee M, Myrehaug S, Tseng CL, et al
    Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04265.
    PubMed     Abstract available


  808. DUFFAU H
    Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04288.
    PubMed     Abstract available


  809. KING AL, Roche KN, Leeper HE, Vera E, et al
    Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial.
    J Neurooncol. 2023 Mar 8:1-9. doi: 10.1007/s11060-023-04271.
    PubMed     Abstract available


  810. JUSINO S, Fadul CE, Dillon P
    Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
    J Neurooncol. 2023 Mar 8. doi: 10.1007/s11060-023-04276.
    PubMed     Abstract available


  811. TRIFILETTI DM, Akinyelu T, Burri SH, Jeudy A, et al
    Glioma inadvertently treated with preoperative stereotactic radiosurgery: focusing on safety.
    J Neurooncol. 2023 Mar 6. doi: 10.1007/s11060-023-04278.
    PubMed    


  812. MARTIN JA, Hart NH, Bradford N, Naumann F, et al
    Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review.
    J Neurooncol. 2023 Mar 2. doi: 10.1007/s11060-023-04270.
    PubMed     Abstract available


  813. LI C, Guan N, Liu F
    T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
    J Neurooncol. 2023 Mar 1. doi: 10.1007/s11060-023-04257.
    PubMed     Abstract available


  814. THIERHEIMER M, Cioffi G, Waite KA, Kruchko C, et al
    Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex.
    J Neurooncol. 2023;162:167-177.
    PubMed     Abstract available


  815. SHARMA M, Do TH, Palzer EF, Huling JD, et al
    Comparable safety profile between neuro-oncology procedures involving stereotactic needle biopsy (SNB) followed by laser interstitial thermal therapy (LITT) and LITT alone procedures.
    J Neurooncol. 2023;162:147-156.
    PubMed     Abstract available


  816. WEI Z, Pease M, Tang LW, Deng H, et al
    Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas.
    J Neurooncol. 2023;162:157-165.
    PubMed     Abstract available


  817. CACCIOTTI C, Chua IS, Cuadra J, Ullrich NJ, et al
    Pediatric central nervous system tumor survivor and caregiver experiences with multidisciplinary telehealth.
    J Neurooncol. 2023;162:191-198.
    PubMed     Abstract available


  818. WESSELS PH, Boelens MC, Monkhorst K, Sonke GS, et al
    A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?
    J Neurooncol. 2023;162:1-13.
    PubMed     Abstract available


    February 2023
  819. TRINGALE KR, Wolden SL, Karajannis M, Haque S, et al
    Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.
    J Neurooncol. 2023 Feb 28. doi: 10.1007/s11060-022-04235.
    PubMed     Abstract available


  820. MOLITERNO J, Brastianos PK
    Journal of Neuro-Oncology, Meningioma issue.
    J Neurooncol. 2023 Feb 27. doi: 10.1007/s11060-023-04251.
    PubMed    


  821. PARK YW, Han K, Kim S, Kwon H, et al
    Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-022-04233.
    PubMed     Abstract available


  822. WANG JZ, Nassiri F, Landry AP, Patil V, et al
    The multiomic landscape of meningiomas: a review and update.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-023-04253.
    PubMed     Abstract available


  823. PATEL Z, Cho M, Das S
    The role of immune checkpoint inhibitors in patients with intracranial metastatic disease.
    J Neurooncol. 2023;161:469-478.
    PubMed     Abstract available


  824. AK M, Lf N, Gm I, Av K, et al
    Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era.
    J Neurooncol. 2023;161:573-582.
    PubMed     Abstract available


    November 2022
  825. IGLESIAS P, Biagetti B, Araujo-Castro M, Alcazar V, et al
    Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
    J Neurooncol. 2022;160:351-359.
    PubMed     Abstract available


  826. RAGHIB MF, Salim A, Angez M, Ghazi SM, et al
    Prognostic implication of size on outcomes of pituitary macroadenoma: a comparative analysis of giant adenoma with non-giant macroadenoma.
    J Neurooncol. 2022;160:491-496.
    PubMed     Abstract available


  827. SHE L, Deng D, Su L, Liu C, et al
    Comparison of surgery with or without adjuvant radiotherapy in treating central neurocytoma: a single-center retrospective real-world study.
    J Neurooncol. 2022;160:455-462.
    PubMed     Abstract available


  828. WEBB M, Johnson DR, Mahajan A, Brown P, et al
    Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis.
    J Neurooncol. 2022;160:527-534.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.